Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Eli Lilly and Company (LLY)
USD1,185.08
-3.50 (-0.29%)
US NYSE S&P 500
Healthcare Drug Manufacturers - General
Address
Lilly Corporate Center 46285
Indianapolis, IN, US
Indianapolis, IN, US
CEO
David A. Ricks
Website
lilly.com
IPO
1972-06-01
CIK 59478 ISIN US5324571083
Also trades on
Deutsche Börse · LLY.DE (EUR)
New York Stock Exchange · LLY (USD)
Swiss Exchange · LLY.SW (CHF)
Toronto Stock Exchange · LLY.TO (CAD)
Description
Eli Lilly and Company is a prominent global pharmaceutical firm dedicated to the research, development, and commercialization of human medicines across the world. Its therapeutic offerings include a comprehensive suite of diabetes medications. This encompasses various insulin formulations like Basaglar, the Humalog family (e.g., Mix 75/25, U-100, U-200, Mix 50/50), insulin lispro products (including protamine and mix 75/25), and the Humulin line (e.g., 70/30, N, R, U-500). Furthermore, Eli Lilly provides specialized treatments for type 2 diabetes, such as Jardiance, Trajenta, and Trulicity. In oncology, Eli Lilly offers a robust portfolio targeting various cancers. These include Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza, indicated for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma; Erbitux for colorectal and various head and neck cancers; Retevmo, used in metastatic NSCLC, medullary thyroid, and other thyroid cancers; Tyvyt for relapsed or refractory classic Hodgkin's lymphoma and non-squamous NSCLC; and Verzenio, prescribed for HR+, HER2- metastatic breast cancer, node-positive, and early breast cancer. For autoimmune and inflammatory conditions, the company markets Olumiant for rheumatoid arthritis, and Taltz, which addresses plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondyloarthritis. Addressing neurological and pain management needs, Eli Lilly provides Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain. Emgality is available for migraine prevention and episodic cluster headaches, while Zyprexa treats schizophrenia, bipolar I disorder, and aids in bipolar maintenance. Other significant products include Bamlanivimab and etesevimab, along with Bebtelovimab, both developed for COVID-19. Cialis is offered for erectile dysfunction and benign prostatic hyperplasia, and Forteo is available for osteoporosis. Eli Lilly actively engages in strategic collaborations with numerous partners, including Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; AbCellera Biologics Inc.; Junshi Biosciences; Regor Therapeutics Group; Lycia Therapeutics, Inc.; Kumquat Biosciences Inc.; Entos Pharmaceuticals Inc.; and Foghorn Therapeutics Inc. Established in 1876, Eli Lilly and Company maintains its corporate headquarters in Indianapolis, Indiana.
News Sentiment (7d)
Market Cap & Enterprise Value
Merger & Acquisition History
| Target company | Date | Filing |
|---|---|---|
| Eli Lilly | 2003-12-19 | View |
Index membership
| Index | Added | Removed | Status |
|---|---|---|---|
| S&P 500 | 1970-11-19 | — | Active |
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
USD1,185.08
-3.50 (-0.29%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
4M
Beta
0.51
Float Shares
850.37M
Free Float %
90.0%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +2.37% | +1.62% | +6.49% | -4.82% | -3.23% | -7.89% | +32.68% | +127.81% | +407.78% | +1,196.83% | +35,126.69% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Analyst Consensus (45 ratings, all time)
Buy
Price Targets & DCF
Current price
1,185.08
Low
1,070.00
-9.7%
Consensus
1,261.11
+6.4%
Median
1,280.00
+8.0%
High
1,400.00
+18.1%
DCF (Unlevered)
625.62
-47.2%
DCF (Levered)
825.54
-30.3%
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
Ratings Trend (MoM)
77% Bullish
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 6 | 0 |
| Buy | 18 | 0 |
| Hold | 6 | 0 |
| Sell | 1 | 0 |
| Strong Sell | 0 | 0 |
Price Target Summary
| Period | # Analysts | Avg Target |
|---|---|---|
| Last Month | 3 |
1,324.67
+11.8%
|
| Last Quarter | 9 |
1,311.00
+10.6%
|
| Last Year | 36 |
1,164.14
-1.8%
|
| All Time | 110 |
795.14
-32.9%
|
Quality scores
Altman Z-Score
8.45
Safe zone
Piotroski F-Score
6 / 9
Average
MOAT Score
6 / 10
Developing
Composite Rating
B+
Overall Score
3 / 5
Medium
DCF Score
4 / 5
High
ROE Score
5 / 5
High
ROA Score
5 / 5
High
D/E Score
1 / 5
Low
P/E Score
2 / 5
Medium
P/Book Score
1 / 5
Low
Operational MOAT
✗ Below peers
★ Strong MOAT
-
Revenue growth Drug Manufacturers - General: +6.6%+44.7% ★ Q1'26: +55.5% (vs Q1'25)
-
EPS growth Drug Manufacturers - General: +18.2%+96.0% ★ Q1'26: +169.9% (vs Q1'25)
-
FCF margin FCF growth · Drug Manufacturers - General: +36.0%+19.0% ★ Q1'26: +15.2% (vs Q1'25)
-
EBIT margin Drug Manufacturers - General: +19.4%+40.5% ★ Q1'26: +44.7% (vs Q1'25)
-
ROIC Drug Manufacturers - General: +10.2%+34.3% ★ Q1'26: +42.7% (vs Q1'25)
-
Share dilution Drug Manufacturers - General: +0.0%-0.7% ★ Q1'26: -0.5% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Drug Manufacturers - General: -0.29×1.52× Q1'26: 1.16× (vs Q1'25)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Dec 2011 actual |
Dec 2012 actual |
Dec 2013 actual |
Dec 2014 actual |
Dec 2015 actual |
Dec 2016 actual |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 19 Rev. Ana. 16 EPS Ana. |
Dec 2027 21 Rev. Ana. 16 EPS Ana. |
Dec 2028 23 Rev. Ana. 8 EPS Ana. |
Dec 2029 11 Rev. Ana. 6 EPS Ana. |
Dec 2030 11 Rev. Ana. 6 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
24.29B
est: 23.54B (+3.2%)
|
22.60B
est: 21.13B (+7.0%)
|
23.11B
est: 21.49B (+7.6%)
|
19.62B
est: 19.40B (+1.1%)
|
19.96B
est: 19.90B (+0.3%)
|
21.22B
est: 20.94B (+1.3%)
|
19.97B
est: 22.64B (-11.8%)
|
21.49B
est: 24.42B (-12.0%)
|
22.32B
est: 22.14B (+0.8%)
|
24.54B
est: 24.38B (+0.7%)
|
28.32B
est: 28.04B (+1.0%)
|
28.54B
est: 28.59B (-0.2%)
|
34.12B
est: 38.92B (-12.3%)
|
45.04B
est: 45.10B (-0.1%)
|
65.18B
est: 63.86B (+2.1%)
|
84.61B
80.64B – 88.35B
+32.5% YoY
|
97.89B
84.96B – 102.68B
+15.7% YoY
|
109.99B
109.97B – 110.01B
+12.4% YoY
|
120.52B
110.96B – 127.70B
+9.6% YoY
|
130.46B
120.11B – 138.23B
+8.2% YoY
|
| EBITDA |
6.91B
est: 6.71B (+3.0%)
|
7.05B
est: 6.59B (+6.9%)
|
7.50B
est: 6.86B (+9.3%)
|
4.53B
est: 4.47B (+1.3%)
|
4.38B
est: 3.77B (+16.3%)
|
5.06B
est: 5.24B (-3.4%)
|
4.10B
est: 3.81B (+7.5%)
|
5.53B
est: 5.20B (+6.4%)
|
6.90B
est: 10.06B (-31.4%)
|
8.91B
est: 7.79B (+14.4%)
|
8.04B
est: 8.30B (-3.1%)
|
8.66B
est: 8.03B (+7.9%)
|
8.57B
est: 12.50B (-31.4%)
|
15.23B
est: 14.48B (+5.2%)
|
27.94B
est: 20.50B (+36.3%)
|
27.16B
25.89B – 28.36B
+32.5% YoY
|
31.43B
27.28B – 32.96B
+15.7% YoY
|
35.31B
35.31B – 35.32B
+12.4% YoY
|
38.69B
35.62B – 41.00B
+9.6% YoY
|
41.88B
38.56B – 44.38B
+8.2% YoY
|
| EBIT |
5.54B
est: 5.37B (+3.0%)
|
5.59B
est: 4.35B (+28.4%)
|
6.05B
est: 4.90B (+23.4%)
|
3.15B
est: 2.62B (+20.1%)
|
2.95B
est: 2.28B (+29.3%)
|
3.56B
est: 3.58B (-0.6%)
|
2.53B
est: 2.05B (+23.7%)
|
3.92B
est: 3.61B (+8.7%)
|
5.67B
est: 4.65B (+21.9%)
|
7.59B
est: 5.30B (+43.1%)
|
6.50B
est: 6.55B (-0.9%)
|
7.14B
est: 8.37B (-14.7%)
|
7.04B
est: 10.81B (-34.9%)
|
13.46B
est: 12.53B (+7.4%)
|
26.37B
est: 17.74B (+48.6%)
|
23.51B
22.41B – 24.55B
+32.5% YoY
|
27.20B
23.61B – 28.53B
+15.7% YoY
|
30.56B
30.56B – 30.57B
+12.4% YoY
|
33.49B
30.83B – 35.48B
+9.6% YoY
|
36.25B
33.37B – 38.41B
+8.2% YoY
|
| Net Income |
4.35B
est: 4.22B (+3.0%)
|
4.09B
est: 3.82B (+6.9%)
|
4.68B
est: 4.28B (+9.5%)
|
2.39B
est: 2.36B (+1.4%)
|
2.41B
est: 2.07B (+16.2%)
|
2.74B
est: 2.84B (-3.5%)
|
-204.10M
est: -161.78M (-26.2%)
|
3.23B
est: 3.02B (+7.0%)
|
8.32B
est: 7.94B (+4.8%)
|
6.19B
est: 5.39B (+14.9%)
|
5.58B
est: 5.76B (-3.1%)
|
6.24B
est: 5.98B (+4.5%)
|
5.24B
est: 7.34B (-28.6%)
|
10.59B
est: 11.60B (-8.7%)
|
20.64B
est: 21.28B (-3.0%)
|
30.78B
25.47B – 36.75B
+44.7% YoY
|
37.54B
35.42B – 42.23B
+21.9% YoY
|
44.65B
40.90B – 52.19B
+18.9% YoY
|
51.65B
46.32B – 55.64B
+15.7% YoY
|
56.93B
51.06B – 61.34B
+10.2% YoY
|
| SGA |
7.88B
est: 7.62B (+3.5%)
|
7.51B
est: 6.94B (+8.3%)
|
7.13B
est: 6.57B (+8.4%)
|
6.62B
est: 6.54B (+1.2%)
|
6.53B
est: 5.71B (+14.4%)
|
6.33B
est: 6.67B (-5.1%)
|
6.18B
est: 6.79B (-9.0%)
|
5.73B
est: 6.06B (-5.4%)
|
6.00B
est: 5.83B (+3.0%)
|
5.87B
est: 6.57B (-10.6%)
|
6.14B
est: 6.65B (-7.7%)
|
6.07B
est: 6.91B (-12.1%)
|
6.94B
est: 7.66B (-9.4%)
|
8.13B
est: 8.87B (-8.3%)
|
11.09B
est: 12.56B (-11.7%)
|
16.65B
15.86B – 17.38B
+32.5% YoY
|
19.26B
16.71B – 20.20B
+15.7% YoY
|
21.64B
21.63B – 21.64B
+12.4% YoY
|
23.71B
21.83B – 25.12B
+9.6% YoY
|
25.66B
23.63B – 27.19B
+8.2% YoY
|
| EPS |
3.90
est: 4.16 (-6.3%)
|
3.57
est: 2.93 (+21.8%)
|
4.19
est: 3.51 (+19.4%)
|
2.15
est: 2.73 (-21.2%)
|
2.18
est: 3.44 (-36.6%)
|
2.49
est: 3.54 (-29.7%)
|
-0.19
est: 4.22 (-104.5%)
|
3.14
est: 5.57 (-43.7%)
|
8.69
est: 5.81 (+49.5%)
|
6.47
est: 7.37 (-12.2%)
|
5.85
est: 8.13 (-28.1%)
|
6.57
est: 7.64 (-14.0%)
|
5.83
est: 8.15 (-28.5%)
|
11.76
est: 12.83 (-8.4%)
|
23.00
est: 23.59 (-2.5%)
|
36.33
28.36 – 40.93
+54.0% YoY
|
44.20
39.44 – 47.02
+21.7% YoY
|
51.23
45.54 – 58.12
+15.9% YoY
|
57.51
51.58 – 61.96
+12.3% YoY
|
63.40
56.86 – 68.30
+10.2% YoY
|
Recent Grade Changes (3M)
| Date | Firm | Previous | New Grade | Action |
|---|---|---|---|---|
| 2026-05-05 | Guggenheim | Buy | Buy | Maintain |
| 2026-05-04 | Wolfe Research | Outperform | Outperform | Maintain |
| 2026-05-01 | Cantor Fitzgerald | Overweight | Overweight | Maintain |
| 2026-04-22 | Guggenheim | Buy | Buy | Maintain |
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-11 | B+ | 3/5 | 4/5 | 5/5 | 5/5 | 1/5 | 2/5 | 1/5 |
| 2026-05-08 | B+ | 3/5 | 4/5 | 5/5 | 5/5 | 1/5 | 2/5 | 1/5 |
| 2026-05-07 | B+ | 3/5 | 4/5 | 5/5 | 5/5 | 1/5 | 2/5 | 1/5 |
| 2026-05-06 | B+ | 3/5 | 4/5 | 5/5 | 5/5 | 1/5 | 2/5 | 1/5 |
| 2026-05-05 | B | 3/5 | 3/5 | 5/5 | 5/5 | 1/5 | 2/5 | 1/5 |
| 2026-05-04 | B | 3/5 | 3/5 | 5/5 | 5/5 | 1/5 | 2/5 | 1/5 |
| 2026-05-01 | B | 3/5 | 3/5 | 5/5 | 5/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-30 | B+ | 3/5 | 4/5 | 5/5 | 5/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-29 | B | 3/5 | 4/5 | 5/5 | 5/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-28 | B | 3/5 | 4/5 | 5/5 | 5/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-27 | B | 3/5 | 4/5 | 5/5 | 5/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-24 | B | 3/5 | 4/5 | 5/5 | 5/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-23 | B | 3/5 | 4/5 | 5/5 | 5/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-22 | B | 3/5 | 4/5 | 5/5 | 5/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-21 | B | 3/5 | 4/5 | 5/5 | 5/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-20 | B | 3/5 | 4/5 | 5/5 | 5/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-17 | B | 3/5 | 4/5 | 5/5 | 5/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-16 | B | 3/5 | 4/5 | 5/5 | 5/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-15 | B | 3/5 | 4/5 | 5/5 | 5/5 | 1/5 | 1/5 | 1/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
22.10B
OE per share TTM
24.61
Owner's Yield
2.55%
Maintenance CapEx ratio
3.58%
Maint CapEx / Avg PPE
36.6%
Ownership Overview
Ownership breakdown
At a glance
Institutional holders
1,981
Total invested
123.21B
Insider transactions (90d)
0
Beneficial owners (>5%)
22
Beneficial owners (>5%)
| # | Reporting person | Amount owned | % of class | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Type | Citizenship | Filing date | SEC filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | LILLY ENDOWMENT INC | 107.46M | 11.23% | 107.46M | — | 107.46M | — | CO | Indiana | 2022-01-27 | ↗ |
| 2 | The Vanguard Group - 23-1945930 | 69.26M | 7.24% | — | 1.36M | 65.92M | 3.34M | IA | — | 2022-02-09 | ↗ |
| 3 | (1) BlackRock, Inc. | 63.88M | 6.70% | 55.68M | — | 63.88M | — | HC | Delaware | 2022-02-08 | ↗ |
| 4 | Wellington Group Holdings LLP | 56.66M | 5.15% | — | 10.29M | — | — | HC | Delaware | 2018-02-08 | ↗ |
| 5 | Wellington Investment Advisors Holdings LLP | 56.66M | 5.15% | — | 10.29M | — | — | HC | Delaware | 2018-02-08 | ↗ |
| 6 | Wellington Management Group LLP | 56.66M | 5.15% | — | 10.29M | — | — | HC | Massachusetts | 2018-02-08 | ↗ |
| 7 | PRIMECAP Management Company 95-3868081 | 54.55M | 4.99% | 11.12M | — | 54.55M | — | IA | 177 E. Colorado Blvd., 11th Floor, Pasadena, CA 91105 | 2018-04-10 | ↗ |
| 8 | 22-1146430 | 51.89M | 5.42% | 1.85M | 50.01M | 1.52M | 50.33M | BK | Pennsylvania | 2022-02-11 | ↗ |
| 9 | 51-0326854 | 51.89M | 5.42% | 1.85M | 50.01M | 1.52M | 50.33M | HC | Pennsylvania | 2022-02-11 | ↗ |
| 10 | Inc. 25-1435979 | 51.89M | 5.42% | 1.85M | 50.01M | 1.52M | 50.33M | HC | Pennsylvania | 2022-02-11 | ↗ |
| 11 | TYTO ACQUISITION CORPORATION | 18.86M | 53.30% | — | 18.86M | — | — | CO | — | 2020-12-22 | ↗ |
| 12 | KEARNY ACQUISITION CORPORATION | 9.64M | 25.50% | — | 9.64M | — | — | CO | — | 2022-10-27 | ↗ |
| 13 | BALD EAGLE ACQUISITION CORPORATION | 7.06M | 12.90% | — | 7.06M | — | — | CO | — | 2020-01-10 | ↗ |
| 14 | OR | 4.00M | 9.70% | 4.00M | — | 4.00M | — | CO | Indiana | 2021-12-13 | ↗ |
| 15 | 35-0470950 | 3.99M | 5.60% | 3.99M | — | 3.99M | — | CO | Indiana | 2021-09-10 | ↗ |
| 16 | Eli Lilly S.A. | 2.55M | 5.80% | — | 2.55M | — | 2.55M | OO | Switzerland | 2022-02-10 | ↗ |
| 17 | Lilly Ventures Fund I LLC | 1.53M | 3.10% | — | 1.53M | — | 1.53M | OO | — | 2022-02-10 | ↗ |
| 18 | ELI LILLY AND COMPANY | 1.01M | 40.30% | 211.1K | 797.7K | 211.1K | — | CO | — | 2023-07-07 | ↗ |
| 19 | SHENANDOAH ACQUISITION CORPORATION | 797.7K | 31.90% | — | 797.7K | — | — | CO | — | 2023-07-07 | ↗ |
| 20 | 27-0640560 | 634.6K | 0.07% | 627.2K | — | 571.9K | 62.3K | IA | Pennsylvania | 2020-02-14 | ↗ |
| 21 | 81-0581990 | 28.5K | 0.01% | 27.5K | — | 20.0K | 8.4K | BK | Pennsylvania | 2022-02-11 | ↗ |
| 22 | 42-1604685 | 16.4K | 0.01% | — | 5.2K | 5.2K | 11.2K | BD | Pennsylvania | 2022-02-11 | ↗ |
Institutional Activity (13F)
Institutional ownership trend
From
To
13F snapshot — 2026 Q1
Investors holding
1,981
-2,545 vs prev Q
New positions
67
Closed positions
2,510
Increased
940
Reduced
773
Put/Call ratio
8.72
Calls held
42.8K
Puts held
373.5K
Top institutional holders
| # | Investor | Shares / Δ | Mkt value / Δ | Own% / Δ | Weight% / Δ | Avg px / Perf. | Hold / Status |
|---|---|---|---|---|---|---|---|
| 1 | LILLY ENDOWMENT INC | 92.19M -3.3M (-3.5%) | 99.08B +26.2B (+36.0%) | 10.28% -0.356 pp | 100.00% +0.000 pp | USD50.16 +2,042.5% | 51 qtrs — |
| 2 | VANGUARD GROUP INC | 81.97M +1.0M (+1.2%) | 88.09B +26.3B (+42.6%) | 9.13% +0.111 pp | 1.28% +0.352 pp | USD197.79 +443.3% | 84 qtrs — |
| 3 | BLACKROCK, INC. | 66.79M +983.1K (+1.5%) | 71.78B +21.6B (+43.0%) | 7.44% +0.109 pp | 1.21% +0.334 pp | USD886.36 +21.2% | 6 qtrs — |
| 4 | PNC FINANCIAL SERVICES GROUP, INC. | 51.33M -31.0K (-0.1%) | 55.17B +16.0B (+40.8%) | 5.72% -0.004 pp | 30.13% +6.358 pp | USD491.50 +118.7% | 51 qtrs — |
| 5 | STATE STREET CORP | 35.36M +635.4K (+1.8%) | 38.00B +11.5B (+43.4%) | 3.94% +0.070 pp | 1.27% +0.356 pp | USD123.18 +772.4% | 51 qtrs — |
| 6 | FMR LLC | 25.72M +1.5M (+6.4%) | 27.64B +9.2B (+49.9%) | 2.86% +0.172 pp | 1.41% +0.451 pp | USD246.01 +336.8% | 70 qtrs — |
| 7 | CAPITAL RESEARCH GLOBAL INVESTORS | 24.57M -521.5K (-2.1%) | 26.40B +7.3B (+37.9%) | 2.74% -0.058 pp | 4.87% +1.282 pp | USD666.44 +61.3% | 15 qtrs — |
| 8 | GEODE CAPITAL MANAGEMENT, LLC | 19.81M -7.8K (0.0%) | 21.22B +6.2B (+40.8%) | 2.21% -0.001 pp | 1.31% +0.348 pp | USD283.25 +279.4% | 78 qtrs — |
| 9 | MORGAN STANLEY | 15.59M +407.2K (+2.7%) | 16.76B +5.2B (+44.6%) | 1.74% +0.045 pp | 1.00% +0.299 pp | USD399.61 +168.9% | 51 qtrs — |
| 10 | CAPITAL WORLD INVESTORS | 15.03M +61.9K (+0.4%) | 16.15B +4.7B (+41.5%) | 1.67% +0.007 pp | 2.20% +0.637 pp | USD238.42 +350.8% | 33 qtrs — |
| 11 | PRICE T ROWE ASSOCIATES INC /MD/ | 14.91M +1.4M (+10.6%) | 16.02B +5.7B (+55.8%) | 1.66% +0.159 pp | 1.73% +0.628 pp | USD309.77 +246.9% | 75 qtrs — |
| 12 | WELLINGTON MANAGEMENT GROUP LLP | 13.36M -1.2M (-8.3%) | 14.35B +3.2B (+29.2%) | 1.49% -0.135 pp | 2.52% +0.571 pp | USD284.43 +277.8% | 81 qtrs — |
| 13 | JPMORGAN CHASE & CO | 13.00M +2.7M (+26.6%) | 13.97B +6.1B (+78.3%) | 1.45% +0.304 pp | 0.88% +0.408 pp | USD470.45 +128.4% | 51 qtrs — |
| 14 | STATE FARM MUTUAL AUTOMOBILE INSURANCE CO | 12.48M +— (+0.0%) | 13.41B +3.9B (+40.8%) | 1.39% 0.000 pp | 10.53% +2.595 pp | USD84.53 +1,171.4% | 108 qtrs — |
| 15 | NORGES BANK | 12.07M +12.1M (+100.0%) | 12.98B +13.0B (+100.0%) | 1.34% +1.345 pp | 1.39% +1.388 pp | USD1,074.68 +0.0% | 1 qtrs NEW |
| 16 | BANK OF AMERICA CORP /DE/ | 11.11M -356.0K (-3.1%) | 11.93B +3.2B (+36.5%) | 1.24% -0.040 pp | 0.87% +0.275 pp | USD279.76 +284.1% | 52 qtrs — |
| 17 | CAPITAL INTERNATIONAL INVESTORS | 9.87M -132.1K (-1.3%) | 10.61B +3.0B (+39.0%) | 1.10% -0.015 pp | 1.66% +0.431 pp | USD428.97 +150.5% | 45 qtrs — |
| 18 | PRIMECAP MANAGEMENT CO/CA/ | 9.27M -1.5M (-14.2%) | 9.96B +1.7B (+20.9%) | 1.03% -0.171 pp | 7.54% +1.229 pp | USD55.03 +1,852.9% | 93 qtrs — |
| 19 | NORTHERN TRUST CORP | 8.84M -63.5K (-0.7%) | 9.50B +2.7B (+39.8%) | 0.98% -0.007 pp | 1.21% +0.342 pp | USD179.11 +500.0% | 51 qtrs — |
| 20 | UBS ASSET MANAGEMENT AMERICAS INC | 6.50M +66.4K (+1.0%) | 6.98B +2.1B (+42.3%) | 0.72% +0.007 pp | 1.48% +0.411 pp | USD456.47 +135.4% | 90 qtrs — |
| 21 | GOLDMAN SACHS GROUP INC | 5.95M -704.9K (-10.6%) | 6.39B +1.3B (+25.9%) | 0.66% -0.078 pp | 0.78% +0.163 pp | USD393.18 +173.3% | 73 qtrs — |
| 22 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 5.76M +125.8K (+2.2%) | 6.19B +1.9B (+44.0%) | 0.64% +0.014 pp | 0.96% +0.276 pp | USD278.75 +285.5% | 100 qtrs — |
| 23 | NUVEEN, LLC | 5.43M +17.8K (+0.3%) | 5.84B +1.7B (+41.3%) | 0.61% +0.002 pp | 1.53% +0.438 pp | USD825.89 +30.1% | 4 qtrs — |
| 24 | LEGAL & GENERAL GROUP PLC | 5.29M -90.4K (-1.7%) | 5.69B +1.6B (+38.5%) | 0.59% -0.010 pp | 1.26% +0.340 pp | USD127.50 +742.9% | 75 qtrs — |
| 25 | JENNISON ASSOCIATES LLC | 5.13M +937.2K (+22.3%) | 5.52B +2.3B (+72.3%) | 0.57% +0.105 pp | 3.31% +1.448 pp | USD441.64 +143.3% | 50 qtrs — |
| 26 | BANK OF NEW YORK MELLON CORP | 5.08M -15.7K (-0.3%) | 5.46B +1.6B (+40.4%) | 0.57% -0.002 pp | 0.97% +0.217 pp | USD103.35 +939.8% | 66 qtrs — |
| 27 | ALLIANCEBERNSTEIN L.P. | 4.62M -188.9K (-3.9%) | 4.97B +1.3B (+35.3%) | 0.51% -0.021 pp | 1.57% +0.413 pp | USD346.26 +210.4% | 61 qtrs — |
| 28 | FRANKLIN RESOURCES INC | 4.62M -221.9K (-4.6%) | 4.96B +1.3B (+34.4%) | 0.51% -0.025 pp | 1.22% +0.297 pp | USD513.40 +109.3% | 51 qtrs — |
| 29 | FISHER ASSET MANAGEMENT, LLC | 4.61M +153.3K (+3.4%) | 4.95B +1.6B (+45.7%) | 0.51% +0.017 pp | 1.69% +0.460 pp | USD337.59 +218.3% | 49 qtrs — |
| 30 | AMUNDI | 4.60M +74.6K (+1.6%) | 4.94B +1.1B (+29.3%) | 0.51% +0.008 pp | 1.34% +0.115 pp | USD511.17 +110.2% | 19 qtrs — |
| 31 | JANUS HENDERSON GROUP PLC | 4.44M -85.9K (-1.9%) | 4.75B +1.3B (+37.6%) | 0.49% -0.010 pp | 2.13% +0.552 pp | USD425.53 +152.6% | 87 qtrs — |
| 32 | SUSQUEHANNA INTERNATIONAL GROUP, LLP | 4.38M -489.9K (-10.1%) | 4.70B +990.7M (+26.7%) | 0.49% -0.055 pp | 0.54% +0.118 pp | USD608.10 +76.7% | 51 qtrs — |
| 33 | ROYAL BANK OF CANADA | 4.37M +314.4K (+7.8%) | 4.70B +1.6B (+51.8%) | 0.49% +0.035 pp | 0.76% +0.257 pp | USD485.32 +121.4% | 51 qtrs — |
| 34 | WELLS FARGO & COMPANY/MN | 4.33M +1.1M (+34.4%) | 4.66B +2.2B (+89.3%) | 0.48% +0.124 pp | 0.85% +0.380 pp | USD415.63 +158.6% | 57 qtrs — |
| 35 | DEUTSCHE BANK AG\ | 3.81M +529.5K (+16.2%) | 4.09B +1.6B (+63.6%) | 0.42% +0.059 pp | 1.33% +0.494 pp | USD469.47 +128.9% | 50 qtrs — |
| 36 | DIMENSIONAL FUND ADVISORS LP | 3.77M +7.7K (+0.2%) | 4.05B +1.2B (+41.2%) | 0.42% +0.001 pp | 0.85% +0.234 pp | USD219.44 +389.7% | 51 qtrs — |
| 37 | UBS GROUP AG | 3.56M -406.3K (-10.2%) | 3.83B +800.8M (+26.4%) | 0.40% -0.045 pp | 0.62% +0.147 pp | USD522.89 +105.5% | 45 qtrs — |
| 38 | JANE STREET GROUP, LLC | 3.14M +1.0M (+48.8%) | 3.37B +1.8B (+109.5%) | 0.35% +0.115 pp | 0.51% +0.264 pp | USD897.58 +19.7% | 6 qtrs — |
| 39 | INVESCO LTD. | 3.01M -27.9K (-0.9%) | 3.24B +917.2M (+39.6%) | 0.34% -0.003 pp | 0.50% +0.131 pp | USD239.91 +348.0% | 57 qtrs — |
| 40 | AMERIPRISE FINANCIAL INC | 2.89M -82.9K (-2.8%) | 3.10B +830.6M (+36.7%) | 0.32% -0.009 pp | 0.70% +0.179 pp | USD172.47 +523.1% | 55 qtrs — |
| 41 | VICTORY CAPITAL MANAGEMENT INC | 2.68M +374.4K (+16.2%) | 2.88B +1.3B (+85.9%) | 0.30% +0.042 pp | 1.63% +0.720 pp | USD690.84 +55.6% | 47 qtrs — |
| 42 | CITADEL ADVISORS LLC | 2.24M -90.8K (-3.9%) | 2.40B +627.8M (+35.4%) | 0.25% -0.010 pp | 0.36% +0.091 pp | USD686.89 +56.5% | 38 qtrs — |
| 43 | SWISS NATIONAL BANK | 2.20M -117.7K (-5.1%) | 2.37B +597.3M (+33.7%) | 0.25% -0.013 pp | 1.41% +0.382 pp | USD154.43 +595.9% | 51 qtrs — |
| 44 | HSBC HOLDINGS PLC | 1.98M +95.2K (+5.0%) | 2.13B +699.9M (+48.8%) | 0.22% +0.011 pp | 1.09% +0.296 pp | USD461.14 +133.0% | 56 qtrs — |
| 45 | SCHRODER INVESTMENT MANAGEMENT GROUP | 1.95M +82.2K (+4.4%) | 2.09B +669.8M (+47.1%) | 0.22% +0.009 pp | 1.60% +0.491 pp | USD295.43 +263.8% | 51 qtrs — |
| 46 | AMERICAN CENTURY COMPANIES INC | 1.86M -99.7K (-5.1%) | 2.00B +504.3M (+33.7%) | 0.21% -0.011 pp | 1.01% +0.244 pp | USD475.28 +126.1% | 51 qtrs — |
| 47 | SUMITOMO MITSUI TRUST HOLDINGS, INC. | 1.86M -102.9K (-5.3%) | 1.99B +500.0M (+33.5%) | 0.21% -0.011 pp | 1.17% +0.312 pp | USD89.67 +1,098.5% | 59 qtrs — |
| 48 | CALIFORNIA PUBLIC EMPLOYEES RETIREMENT SYSTEM | 1.85M -72.1K (-3.7%) | 1.99B +523.0M (+35.6%) | 0.21% -0.008 pp | 1.14% +0.260 pp | USD188.05 +471.5% | 53 qtrs — |
| 49 | NEUBERGER BERMAN GROUP LLC | 1.78M +28.6K (+1.6%) | 1.91B +575.6M (+43.2%) | 0.20% +0.003 pp | 1.42% +0.447 pp | USD322.83 +232.9% | 51 qtrs — |
| 50 | MITSUBISHI UFJ KOKUSAI ASSET MANAGEMENT CO., LTD. | 1.75M +97.1K (+5.9%) | 1.89B +629.9M (+49.9%) | 0.20% +0.011 pp | 1.28% +0.374 pp | USD582.74 +84.4% | 58 qtrs — |
| 51 | SWEDBANK AB | 1.67M +115.7K (+7.4%) | 1.79B +608.4M (+51.3%) | 0.19% +0.013 pp | 1.74% +0.534 pp | USD474.85 +126.3% | 20 qtrs — |
| 52 | BANK OF MONTREAL /CAN/ | 1.63M +59.5K (+3.8%) | 1.75B +553.3M (+46.2%) | 0.18% +0.007 pp | 0.61% +0.147 pp | USD341.24 +214.9% | 51 qtrs — |
| 53 | NATIONAL PENSION SERVICE | 1.62M +23.4K (+1.5%) | 1.74B +521.4M (+42.9%) | 0.18% +0.003 pp | 1.29% +0.342 pp | USD324.81 +230.9% | 46 qtrs — |
| 54 | SAPIENT CAPITAL LLC | 1.50M +20.7K (+1.4%) | 1.62B +543.9M (+50.6%) | 0.17% +0.002 pp | 22.72% +6.188 pp | USD628.82 +70.9% | 9 qtrs — |
| 55 | RAYMOND JAMES FINANCIAL INC | 1.49M +109.2K (+7.9%) | 1.60B +547.9M (+52.0%) | 0.17% +0.012 pp | 0.50% +0.160 pp | USD794.29 +35.3% | 5 qtrs — |
| 56 | COMERICA BANK | 1.49M -9.4K (-0.6%) | 1.60B +455.8M (+40.0%) | 0.17% -0.001 pp | 6.37% +2.079 pp | USD701.94 +53.1% | 10 qtrs — |
| 57 | NORDEA INVESTMENT MANAGEMENT AB | 1.48M +110.0K (+8.0%) | 1.59B +598.6M (+60.1%) | 0.17% +0.012 pp | 1.37% +0.497 pp | USD595.45 +80.5% | 88 qtrs — |
| 58 | VOYA INVESTMENT MANAGEMENT LLC | 1.46M +680.3K (+87.2%) | 1.57B +974.0M (+163.8%) | 0.16% +0.076 pp | 1.55% +0.953 pp | USD730.21 +47.2% | 51 qtrs — |
| 59 | BARCLAYS PLC | 1.40M -158.2K (-10.1%) | 1.51B +124.8M (+9.0%) | 0.16% -0.018 pp | 0.36% +0.007 pp | USD512.68 +109.6% | 51 qtrs — |
| 60 | MANUFACTURERS LIFE INSURANCE COMPANY, THE | 1.40M -172.9K (-11.0%) | 1.51B +305.8M (+25.5%) | 0.16% -0.019 pp | 1.24% +0.251 pp | USD156.21 +588.0% | 108 qtrs — |
| 61 | RHUMBLINE ADVISERS | 1.39M -51.3K (-3.6%) | 1.49B +394.0M (+35.8%) | 0.15% -0.006 pp | 1.21% +0.324 pp | USD128.73 +734.8% | 55 qtrs — |
| 62 | US BANCORP \DE\ | 1.37M -3.9K (-0.3%) | 1.47B +424.1M (+40.4%) | 0.15% 0.000 pp | 1.73% +0.483 pp | USD98.13 +995.2% | 51 qtrs — |
| 63 | CANADA PENSION PLAN INVESTMENT BOARD | 1.33M +80.0K (+6.4%) | 1.43B +475.0M (+49.9%) | 0.15% +0.009 pp | 0.95% +0.286 pp | USD636.62 +68.8% | 52 qtrs — |
| 64 | PRINCIPAL FINANCIAL GROUP INC | 1.27M +15.8K (+1.3%) | 1.36B +407.8M (+42.6%) | 0.14% +0.002 pp | 0.70% +0.214 pp | USD215.65 +398.3% | 81 qtrs — |
| 65 | EDGEWOOD MANAGEMENT LLC | 1.26M -923.7K (-42.4%) | 1.35B -313.4M (-18.8%) | 0.14% -0.103 pp | 6.43% +0.534 pp | USD457.37 +135.0% | 12 qtrs — |
| 66 | POLEN CAPITAL MANAGEMENT LLC | 1.25M -376.9K (-23.2%) | 1.34B +100.8M (+8.1%) | 0.14% -0.042 pp | 5.72% +1.698 pp | USD720.52 +49.2% | 10 qtrs — |
| 67 | CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM | 1.24M -23.8K (-1.9%) | 1.34B +369.7M (+38.2%) | 0.14% -0.003 pp | 1.34% +0.345 pp | USD87.63 +1,126.4% | 52 qtrs — |
| 68 | MARSHALL WACE, LLP | 1.21M +1.0M (+640.9%) | 1.30B +1.2B (+943.6%) | 0.13% +0.116 pp | 1.18% +1.056 pp | USD1,032.07 +4.1% | 25 qtrs — |
| 69 | TD ASSET MANAGEMENT INC | 1.18M +277.6K (+30.6%) | 1.27B +580.9M (+84.0%) | 0.13% +0.031 pp | 1.02% +0.462 pp | USD456.38 +135.5% | 51 qtrs — |
| 70 | LPL FINANCIAL LLC | 1.17M +50.3K (+4.5%) | 1.26B +403.6M (+47.2%) | 0.13% +0.006 pp | 0.34% +0.095 pp | USD544.60 +97.3% | 51 qtrs — |
| 71 | ENVESTNET ASSET MANAGEMENT INC | 1.11M -59.6K (-5.1%) | 1.19B +299.4M (+33.7%) | 0.12% -0.007 pp | 0.35% +0.097 pp | USD509.78 +110.8% | 51 qtrs — |
| 72 | T. ROWE PRICE INVESTMENT MANAGEMENT, INC. | 1.10M +6.2K (+0.6%) | 1.18B +347.8M (+41.6%) | 0.12% +0.001 pp | 0.75% +0.236 pp | USD529.14 +103.1% | 13 qtrs — |
| 73 | PARNASSUS INVESTMENTS, LLC | 1.01M +382.1K (+60.8%) | 1.09B +606.5M (+126.5%) | 0.11% +0.043 pp | 2.82% +1.708 pp | USD886.18 +21.3% | 13 qtrs — |
| 74 | DZ BANK AG DEUTSCHE ZENTRAL GENOSSENSCHAFTS BANK, FRANKFURT AM MAIN | 984.2K -67.8K (-6.4%) | 1.06B +255.3M (+31.8%) | 0.11% -0.008 pp | 0.91% +0.211 pp | USD477.67 +125.0% | 37 qtrs — |
| 75 | BNP PARIBAS ASSET MANAGEMENT HOLDING S.A. | 937.3K +272.1K (+40.9%) | 1.01B +500.8M (+98.9%) | 0.10% +0.030 pp | 1.16% -0.157 pp | USD680.93 +57.8% | 51 qtrs — |
| 76 | NEW YORK STATE COMMON RETIREMENT FUND | 913.8K -12.1K (-1.3%) | 982.03M +275.6M (+39.0%) | 0.10% -0.001 pp | 1.31% +0.397 pp | USD65.76 +1,534.2% | 103 qtrs — |
| 77 | PICTET ASSET MANAGEMENT HOLDING SA | 880.5K +190.1K (+27.5%) | 946.31M +419.9M (+79.8%) | 0.10% +0.021 pp | 0.92% +0.411 pp | USD687.94 +56.2% | 10 qtrs — |
| 78 | ENSIGN PEAK ADVISORS, INC | 837.7K +210.6K (+33.6%) | 900.21M +421.8M (+88.2%) | 0.09% +0.023 pp | 1.59% +0.805 pp | USD613.79 +75.1% | 25 qtrs — |
| 79 | ADAGE CAPITAL PARTNERS GP, L.L.C. | 832.3K +25.4K (+3.2%) | 894.45M +278.8M (+45.3%) | 0.09% +0.003 pp | 1.35% +0.379 pp | USD339.33 +216.7% | 55 qtrs — |
| 80 | STIFEL FINANCIAL CORP | 793.6K +3.4K (+0.4%) | 852.97M +250.0M (+41.5%) | 0.09% +0.000 pp | 0.77% +0.217 pp | USD278.15 +286.4% | 48 qtrs — |
| 81 | BAHL & GAYNOR INC | 787.4K -16.6K (-2.1%) | 846.18M +232.7M (+37.9%) | 0.09% -0.002 pp | 4.28% +1.237 pp | USD182.81 +487.9% | 53 qtrs — |
| 82 | HANDELSBANKEN FONDER AB | 764.8K -87.7K (-10.3%) | 821.90M +171.4M (+26.4%) | 0.09% -0.010 pp | 2.48% +0.417 pp | USD243.49 +341.4% | 41 qtrs — |
| 83 | CIBC PRIVATE WEALTH GROUP, LLC | 762.2K +208.9K (+37.7%) | 819.17M +397.0M (+94.0%) | 0.08% +0.023 pp | 1.38% +0.662 pp | USD507.39 +111.8% | 48 qtrs — |
| 84 | WINSLOW CAPITAL MANAGEMENT, LLC | 757.2K -19.9K (-2.6%) | 816.55M +223.6M (+37.7%) | 0.08% -0.002 pp | 2.74% +0.781 pp | USD674.57 +59.3% | 11 qtrs — |
| 85 | PRUDENTIAL FINANCIAL INC | 753.3K +14.0K (+1.9%) | 809.51M +245.5M (+43.5%) | 0.08% +0.002 pp | 0.98% +0.307 pp | USD376.60 +185.4% | 85 qtrs — |
| 86 | BANK JULIUS BAER & CO. LTD, ZURICH | 748.1K -44.8K (-5.6%) | 804.39M +199.5M (+33.0%) | 0.08% -0.005 pp | 2.22% +0.514 pp | USD763.96 +40.7% | 24 qtrs — |
| 87 | ABRDN PLC | 747.2K -97.8K (-11.6%) | 803.03M +184.7M (+29.9%) | 0.08% -0.011 pp | 1.24% +0.265 pp | USD262.65 +309.2% | 34 qtrs — |
| 88 | APG ASSET MANAGEMENT N.V. | 875.5K +969.0 (+0.1%) | 801.15M +233.2M (+41.1%) | 0.10% +0.000 pp | 2.27% +0.680 pp | USD702.96 +52.9% | 51 qtrs — |
| 89 | ROYAL LONDON ASSET MANAGEMENT LTD | 739.8K -5.5K (-0.7%) | 795.08M +226.4M (+39.8%) | 0.08% -0.001 pp | 1.67% +0.451 pp | USD279.87 +284.0% | 31 qtrs — |
| 90 | GRANTHAM, MAYO, VAN OTTERLOO & CO. LLC | 739.3K +38.7K (+5.5%) | 794.48M +259.9M (+48.6%) | 0.08% +0.004 pp | 2.03% +0.523 pp | USD435.77 +146.6% | 77 qtrs — |
| 91 | NATIXIS ADVISORS, L.P. | 728.5K +27.8K (+4.0%) | 782.85M +248.2M (+46.4%) | 0.08% +0.003 pp | 1.11% +0.329 pp | USD451.46 +138.0% | 57 qtrs — |
| 92 | ROBECO INSTITUTIONAL ASSET MANAGEMENT B.V. | 726.5K -89.3K (-11.0%) | 780.72M +158.3M (+25.4%) | 0.08% -0.010 pp | 1.11% +0.210 pp | USD409.76 +162.3% | 74 qtrs — |
| 93 | STATE BOARD OF ADMINISTRATION OF FLORIDA RETIREMENT SYSTEM | 711.6K -21.9K (-3.0%) | 764.73M +205.1M (+36.7%) | 0.08% -0.002 pp | 1.35% +0.374 pp | USD90.77 +1,084.0% | 51 qtrs — |
| 94 | BNP PARIBAS ARBITRAGE, SNC | 709.2K +233.3K (+49.0%) | 762.16M +399.1M (+109.9%) | 0.08% +0.026 pp | 0.35% +0.152 pp | USD800.64 +34.2% | 51 qtrs — |
| 95 | DEKABANK DEUTSCHE GIROZENTRALE | 915.4K +— (+0.0%) | 746.03M +81.7M (+12.3%) | 0.10% +0.000 pp | 1.29% +0.172 pp | USD261.71 +310.6% | 66 qtrs — |
| 96 | ACTIAM N.V. | 2.38M +2.1M (+876.1%) | 255.24M +69.6M (+37.5%) | 0.26% +0.237 pp | 2.58% +0.609 pp | USD1,032.08 +4.1% | 9 qtrs — |
| 97 | J. STERN & CO. LLP | 4.05M +4.0M (+46,191.3%) | 4.05M -2.6M (-39.3%) | 0.45% +0.450 pp | 0.34% -0.160 pp | USD1,074.12 +0.1% | 9 qtrs — |
Ownership breakdown by holder
Insider Activity
Insider Activity — Latest Quarter
Ratio by transactions
0.00
Bearish
Buys
4
Sells
0
Shares acquired
46.97
Shares disposed
—
Cash buys
—
Cash sales
—
Net activity
+47
Insider buys vs sells (history)
From
To
Recent insider transactions
No recent insider transactions.
Executive team
Top executives
EBIT / Employee
561.1K
Shares Outstanding
944.82M
Executive compensation
Executive compensation (annual)
| # | Year | Executive | Salary | Bonus | Stock award | Option award | Incentive | Other | Total | % Stock- based |
Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 2025 | David A. Ricks Chair, President, and Chief Executive Officer | 1.70M | — | 23.33M | — | 6.49M | 5.19M | 36.70M | 63.56% | ↗ |
| 2 | 2025 | Daniel M. Skovronsky, M.D., Ph.D. Executive Vice President, Chief Scientific and Product Officer and President, Lilly Research Labs | 1.49M | — | 12.00M | — | 3.25M | 1.05M | 17.79M | 67.47% | ↗ |
| 3 | 2025 | Anat Hakim Executive Vice President, General Counsel and Secretary | 1.00M | — | 6.00M | — | 2.18M | 665.5K | 9.85M | 60.94% | ↗ |
| 4 | 2025 | Lucas Montarce Executive Vice President and Chief Financial Officer | 1.00M | — | 5.00M | — | 2.18M | 303.3K | 8.48M | 58.94% | ↗ |
| 5 | 2025 | Jake Van Naarden Executive Vice President and President, Lilly Oncology and Head of Corporate Business Development | 920.2K | — | 4.50M | — | 2.01M | 159.9K | 7.59M | 59.32% | ↗ |
| 6 | 2024 | David A. Ricks Chair, President, and Chief Executive Officer | 1.69M | — | 19.75M | — | 5.71M | 2.10M | 29.24M | 67.54% | ↗ |
| 7 | 2024 | Daniel M. Skovronsky, M.D., Ph.D. Executive Vice President, Chief Scientific Officer and President, Lilly Research Laboratories and Lilly Immunology | 1.43M | — | 7.50M | — | 3.22M | 488.9K | 12.64M | 59.34% | ↗ |
| 8 | 2024 | Daniel M. Skovronsky, M.D., Ph.D. Executive Vice President, Chief Scientific and Product Officer and President, Lilly Research Labs | 1.43M | — | 7.50M | — | 3.22M | 488.9K | 12.64M | 59.34% | ↗ |
| 9 | 2024 | Anat Hakim Executive Vice President, General Counsel and Secretary | 1.00M | — | 3.95M | — | 2.25M | 278.4K | 7.48M | 52.82% | ↗ |
| 10 | 2024 | Jake Van Naarden Executive Vice President and President, Loxo@Lilly | 890.4K | — | 2.70M | — | 2.00M | 179.9K | 5.77M | 46.77% | ↗ |
| 11 | 2024 | Jake Van Naarden Executive Vice President and President, Lilly Oncology and Head of Corporate Business Development | 890.4K | — | 2.70M | — | 2.00M | 179.9K | 5.77M | 46.77% | ↗ |
| 12 | 2024 | Anat Ashkenazi Executive Vice President and Chief Financial Officer | 634.0K | — | 3.75M | — | — | 576.9K | 4.96M | 75.59% | ↗ |
| 13 | 2024 | Lucas Montarce Executive Vice President and Chief Financial Officer | 664.6K | — | 1.07M | — | 1.11M | 102.2K | 2.95M | 36.19% | ↗ |
| 14 | 2024 | Gordon Brooks Interim CFO and Group Vice President - Controller and Corporate Strategy | 558.3K | 50.0K | 1.30M | — | 667.7K | 164.3K | 2.74M | 47.44% | ↗ |
| 15 | 2023 | David A. Ricks Chair, President, and Chief Executive Officer | 1.62M | — | 18.84M | — | 4.40M | 1.70M | 26.57M | 70.92% | ↗ |
| 16 | 2023 | Daniel M. Skovronsky, M.D., Ph.D. Executive Vice President, Chief Scientific Officer and President, Lilly Research Laboratories and Lilly Immunology | 1.33M | — | 7.48M | — | 2.41M | 631.1K | 11.85M | 63.13% | ↗ |
| 17 | 2023 | Daniel M. Skovronsky, M.D., Ph.D. Executive Vice President, Chief Scientific and Product Officer and President, Lilly Research Labs | 1.33M | — | 7.48M | — | 2.41M | 631.1K | 11.85M | 63.13% | ↗ |
| 18 | 2023 | Anat Ashkenazi Executive Vice President and Chief Financial Officer | 1.03M | — | 3.69M | — | 1.87M | 1.01M | 7.60M | 48.54% | ↗ |
| 19 | 2023 | Anat Hakim Executive Vice President, General Counsel and Secretary | 980.8K | — | 3.95M | — | 1.78M | 298.3K | 7.01M | 56.41% | ↗ |
| 20 | 2023 | Jake Van Naarden Executive Vice President and President, Lilly Oncology and Head of Corporate Business Development | 830.8K | — | 2.42M | — | 1.50M | 127.9K | 4.89M | 49.61% | ↗ |
| 21 | 2023 | Jake Van Naarden Executive Vice President and President, Loxo@Lilly | 830.8K | — | 2.42M | — | 1.50M | 127.9K | 4.89M | 49.61% | ↗ |
| 22 | 2022 | David A. Ricks Chair, President, and Chief Executive Officer | 1.50M | — | 16.98M | — | 2.70M | 216.9K | 21.40M | 79.36% | ↗ |
| 23 | 2022 | Daniel M. Skovronsky, M.D., Ph.D. Executive Vice President, Chief Scientific Officer and President, Lilly Research Laboratories and Lilly Immunology | 1.20M | — | 5.75M | — | 1.44M | 72.1K | 8.46M | 67.91% | ↗ |
| 24 | 2022 | Daniel M. Skovronsky, M.D., Ph.D. Executive Vice President, Chief Scientific and Medical Officer and President, Lilly Research Laboratories | 1.20M | — | 5.75M | — | 1.44M | 72.1K | 8.46M | 67.91% | ↗ |
| 25 | 2022 | Anat Hakim Executive Vice President, General Counsel and Secretary | 876.0K | — | 3.14M | — | 1.05M | 199.4K | 5.26M | 59.58% | ↗ |
| 26 | 2022 | Anat Ashkenazi Executive Vice President and Chief Financial Officer | 940.4K | — | 3.14M | — | 1.13M | 56.4K | 5.26M | 59.60% | ↗ |
| 27 | 2022 | Patrik Jonsson Executive Vice President and President, Lilly Immunology, Lilly USA and Chief Customer Officer | 740.4K | — | 2.19M | — | 888.5K | 99.9K | 3.92M | 55.94% | ↗ |
| 28 | 2022 | Jake Van Naarden Executive Vice President and President, Loxo@Lilly | 735.6K | — | 1.93M | — | 882.7K | 70.3K | 3.62M | 53.38% | ↗ |
| 29 | 2021 | David A. Ricks Chair, President, and Chief Executive Officer | 1.50M | — | 14.97M | — | 2.48M | 2.57M | 21.51M | 69.58% | ↗ |
| 30 | 2021 | Daniel M. Skovronsky, M.D., Ph.D. Senior Vice President, Chief Scientific and Medical Officer and President, Lilly Research Laboratories | 1.00M | — | 5.02M | — | 1.10M | 402.8K | 7.53M | 66.75% | ↗ |
| 31 | 2021 | Daniel M. Skovronsky, M.D., Ph.D. Executive Vice President, Chief Scientific Officer and President, Lilly Research Laboratories and Lilly Immunology | 1.00M | — | 5.02M | — | 1.10M | 402.8K | 7.53M | 66.75% | ↗ |
| 32 | 2021 | Daniel M. Skovronsky, M.D., Ph.D. Executive Vice President, Chief Scientific and Medical Officer and President, Lilly Research Laboratories | 1.00M | — | 5.02M | — | 1.10M | 402.8K | 7.53M | 66.75% | ↗ |
| 33 | 2021 | Jake Van Naarden Executive Vice President and President, Loxo@Lilly | 745.6K | 218.7K | 4.10M | — | 1.03M | 29.4K | 6.12M | 66.96% | ↗ |
| 34 | 2021 | Jacob Van Naarden Senior Vice President, CEO Loxo Oncology at Lilly and President, Lilly Oncology | 745.6K | 218.7K | 4.10M | — | 1.03M | 29.4K | 6.12M | 66.96% | ↗ |
| 35 | 2021 | Diogo Rau Senior Vice President and Chief Information and Digital Officer | 412.3K | 250.0K | 4.00M | — | 362.8K | 76.2K | 5.10M | 78.41% | ↗ |
| 36 | 2021 | Anat Ashkenazi Senior Vice President and Chief Financial Officer | 850.4K | — | 2.45M | — | 907.8K | 446.4K | 4.66M | 52.67% | ↗ |
| 37 | 2021 | Anat Ashkenazi Executive Vice President and Chief Financial Officer | 850.4K | — | 2.45M | — | 906.9K | 446.4K | 4.66M | 52.68% | ↗ |
| 38 | 2021 | Anat Hakim Executive Vice President, General Counsel and Secretary | 775.0K | — | 2.24M | — | 852.5K | 145.5K | 4.02M | 55.87% | ↗ |
| 39 | 2021 | Joshua L. Smiley Former Senior Vice President and Chief Financial Officer | 230.8K | — | — | — | — | 13.9K | 244.7K | 0.00% | ↗ |
| 40 | 2020 | David A. Ricks Chair, President, and Chief Executive Officer | 1.48M | — | 13.59M | — | 2.63M | 6.01M | 23.71M | 57.31% | ↗ |
| 41 | 2020 | David A. Ricks Chairman, President, and Chief Executive Officer | 1.48M | — | 13.59M | — | 2.63M | 6.01M | 23.71M | 57.31% | ↗ |
| 42 | 2020 | Daniel M. Skovronsky, M.D., Ph.D. Senior Vice President, Chief Scientific and Medical Officer and President, Lilly Research Laboratories | 983.3K | — | 4.46M | — | 1.10M | 809.8K | 7.35M | 60.62% | ↗ |
| 43 | 2020 | Daniel M. Skovronsky, M.D., Ph.D. Senior Vice President, Chief Scientific Officer, and President, Lilly Research Laboratories | 983.3K | — | 4.46M | — | 1.10M | 809.8K | 7.35M | 60.62% | ↗ |
| 44 | 2020 | Daniel M. Skovronsky, M.D., Ph.D. Executive Vice President, Chief Scientific and Medical Officer and President, Lilly Research Laboratories | 983.3K | — | 4.46M | — | 1.10M | 809.8K | 7.35M | 60.62% | ↗ |
| 45 | 2020 | Joshua L. Smiley Former Senior Vice President and Chief Financial Officer | 983.3K | — | 3.59M | — | — | 2.74M | 7.31M | 49.04% | ↗ |
| 46 | 2020 | Alfonso G. Zulueta Senior Vice President and President, Lilly International | 850.0K | — | 2.45M | — | 952.9K | 2.32M | 6.57M | 37.24% | ↗ |
| 47 | 2020 | Anat Hakim Senior Vice President, General Counsel and Secretary | 710.4K | 150.0K | 4.17M | — | 670.6K | 212.8K | 5.92M | 70.53% | ↗ |
| 48 | 2020 | Anat Hakim Executive Vice President, General Counsel and Secretary | 710.4K | 150.0K | 4.17M | — | 670.6K | 212.8K | 5.92M | 70.53% | ↗ |
| 49 | 2019 | David A. Ricks Chairman, President, and Chief Executive Officer | 1.40M | — | 12.22M | — | 2.92M | 4.74M | 21.28M | 57.43% | ↗ |
| 50 | 2019 | David A. Ricks Chair, President, and Chief Executive Officer | 1.40M | — | 12.22M | — | 2.92M | 4.74M | 21.28M | 57.43% | ↗ |
| 51 | 2019 | Michael J. Harrington (retired) Senior Vice President and General Counsel | 893.4K | — | 2.97M | — | 993.4K | 2.64M | 7.50M | 39.60% | ↗ |
| 52 | 2019 | Joshua L. Smiley Senior Vice President and Chief Financial Officer | 895.8K | — | 3.14M | — | 1.18M | 2.13M | 7.35M | 42.77% | ↗ |
| 53 | 2019 | Joshua L. Smiley Former Senior Vice President and Chief Financial Officer | 895.8K | — | 3.14M | — | 1.18M | 2.13M | 7.35M | 42.77% | ↗ |
| 54 | 2019 | Enrique A. Conterno (retired) Senior Vice President and President, Lilly Diabetes and President, Lilly USA | 833.3K | — | 3.03M | — | 1.10M | 2.22M | 7.18M | 42.18% | ↗ |
| 55 | 2019 | Daniel M. Skovronsky, M.D., Ph.D. Senior Vice President, Chief Scientific and Medical Officer and President, Lilly Research Laboratories | 900.0K | — | 4.07M | — | 1.19M | 500.5K | 6.66M | 61.14% | ↗ |
| 56 | 2019 | Daniel M. Skovronsky, M.D., Ph.D. Senior Vice President, Chief Scientific Officer, and President, Lilly Research Laboratories | 900.0K | — | 4.07M | — | 1.19M | 500.5K | 6.66M | 61.14% | ↗ |
| 57 | 2018 | David A. Ricks Chairman, President, and Chief Executive Officer | 1.40M | — | 10.58M | — | 3.63M | 1.61M | 17.23M | 61.43% | ↗ |
| 58 | 2018 | Michael J. Harrington Senior Vice President and General Counsel | 860.3K | — | 3.00M | — | 1.19M | 390.6K | 5.44M | 55.12% | ↗ |
| 59 | 2018 | Michael J. Harrington (retired) Senior Vice President and General Counsel | 860.3K | — | 3.00M | — | 1.19M | 390.6K | 5.44M | 55.12% | ↗ |
| 60 | 2018 | Jeffrey N. Simmons President, Chief Executive Officer and Director Elanco Animal Health, Inc. | 775.2K | — | 2.53M | 1.12M | 907.5K | 46.5K | 5.38M | 67.86% | ↗ |
| 61 | 2018 | Joshua L. Smiley Senior Vice President and Chief Financial Officer | 875.0K | — | 2.70M | — | 1.44M | 227.5K | 5.25M | 51.57% | ↗ |
| 62 | 2018 | Joshua L. Smiley Former Senior Vice President and Chief Financial Officer | 875.0K | — | 2.70M | — | 1.44M | 227.5K | 5.25M | 51.57% | ↗ |
| 63 | 2018 | Daniel M. Skovronsky, M.D., Ph.D. Senior Vice President, Chief Scientific Officer, and President, Lilly Research Laboratories | 837.5K | — | 2.81M | — | 1.38M | 126.0K | 5.15M | 54.53% | ↗ |
| 64 | 2018 | Daniel M. Skovronsky, M.D., Ph.D. Senior Vice President and Chief Scientific Officer | 837.5K | — | 2.81M | — | 1.38M | 126.0K | 5.15M | 54.53% | ↗ |
| 65 | 2018 | Enrique A. Conterno Senior Vice President and President, Lilly Diabetes and President, Lilly USA | 794.7K | — | 3.06M | — | 1.10M | 47.7K | 5.00M | 61.15% | ↗ |
| 66 | 2018 | Enrique A. Conterno (retired) Senior Vice President and President, Lilly Diabetes and President, Lilly USA | 794.7K | — | 3.06M | — | 1.10M | 47.7K | 5.00M | 61.15% | ↗ |
| 67 | 2017 | David A. Ricks Chairman, President, and Chief Executive Officer | 1.40M | — | 10.20M | — | 2.81M | 1.43M | 15.85M | 64.37% | ↗ |
| 68 | 2017 | Derica W. Rice (retired) Executive Vice President, Global Services and Chief Financial Officer | 1.09M | — | 4.56M | — | 1.46M | 1.79M | 8.89M | 51.27% | ↗ |
| 69 | 2017 | Enrique A. Conterno (retired) Senior Vice President and President, Lilly Diabetes and President, Lilly USA | 762.0K | — | 6.00M | — | 816.9K | 1.05M | 8.62M | 69.57% | ↗ |
| 70 | 2017 | Enrique A. Conterno Senior Vice President and President, Lilly Diabetes and President, Lilly USA | 762.0K | — | 6.00M | — | 816.9K | 1.05M | 8.62M | 69.57% | ↗ |
| 71 | 2017 | Jan M. Lundberg, Ph.D. Executive Vice President, Science and Technology and President, Lilly Research Laboratories | 1.02M | — | 4.32M | — | 1.37M | 679.8K | 7.40M | 58.40% | ↗ |
| 72 | 2017 | Michael J. Harrington (retired) Senior Vice President and General Counsel | 856.1K | — | 2.76M | — | 917.8K | 1.71M | 6.24M | 44.21% | ↗ |
| 73 | 2017 | Michael J. Harrington Senior Vice President and General Counsel | 856.1K | — | 2.76M | — | 917.8K | 1.71M | 6.24M | 44.21% | ↗ |
| 74 | 2016 | John C. Lechleiter, Ph.D. Chairman, President, and Chief Executive Officer | 1.50M | — | 11.00M | — | 2.63M | 3.23M | 18.37M | 59.89% | ↗ |
| 75 | 2016 | Derica W. Rice (retired) Executive Vice President, Global Services and Chief Financial Officer | 1.07M | — | 3.80M | — | 1.25M | 1.80M | 7.92M | 47.98% | ↗ |
| 76 | 2016 | Derica W. Rice Executive Vice President, Global Services, and Chief Financial Officer | 1.07M | — | 3.80M | — | 1.25M | 1.80M | 7.92M | 47.98% | ↗ |
| 77 | 2016 | Jan M. Lundberg, Ph.D. Executive Vice President, Science and Technology and President, Lilly Research Laboratories | 1.01M | — | 3.60M | — | 1.18M | 687.9K | 6.47M | 55.60% | ↗ |
| 78 | 2016 | Jan M. Lundberg, Ph.D. Executive Vice President, Science and Technology, and President, Lilly Research Laboratories | 1.01M | — | 3.60M | — | 1.18M | 687.9K | 6.47M | 55.60% | ↗ |
| 79 | 2016 | Michael J. Harrington Senior Vice President and General Counsel | 827.4K | — | 2.30M | — | 774.4K | 1.49M | 5.39M | 42.64% | ↗ |
| 80 | 2016 | Enrique A. Conterno Senior Vice President and President, Lilly Diabetes | 728.0K | — | 2.20M | — | 681.4K | 979.1K | 4.59M | 47.95% | ↗ |
| 81 | 2016 | Enrique A. Conterno Senior Vice President and President, Lilly Diabetes and President, Lilly USA | 728.0K | — | 2.20M | — | 681.4K | 979.1K | 4.59M | 47.95% | ↗ |
| 82 | 2015 | John C. Lechleiter, Ph.D. Chairman, President, and Chief Executive Officer | 1.50M | — | 11.35M | — | 3.62M | 90.0K | 16.56M | 68.53% | ↗ |
| 83 | 2015 | Derica W. Rice (retired) Executive Vice President, Global Services and Chief Financial Officer | 1.05M | — | 4.31M | — | 1.51M | 62.7K | 6.94M | 62.19% | ↗ |
| 84 | 2015 | Derica W. Rice Executive Vice President, Global Services and Chief Financial Officer | 1.05M | — | 4.31M | — | 1.51M | 62.7K | 6.94M | 62.19% | ↗ |
| 85 | 2015 | Derica W. Rice Executive Vice President, Global Services, and Chief Financial Officer | 1.05M | — | 4.31M | — | 1.51M | 62.7K | 6.94M | 62.19% | ↗ |
| 86 | 2015 | Jan M. Lundberg, Ph.D. Executive Vice President, Science and Technology and President, Lilly Research Laboratories | 1.01M | — | 3.86M | — | 1.46M | 451.1K | 6.78M | 56.93% | ↗ |
| 87 | 2015 | Jan M. Lundberg, Ph.D. Executive Vice President, Science and Technology, and President, Lilly Research Laboratories | 1.01M | — | 3.86M | — | 1.46M | 451.1K | 6.78M | 56.93% | ↗ |
| 88 | 2015 | Michael J. Harrington Senior Vice President and General Counsel | 784.2K | — | 2.61M | — | 946.9K | 438.9K | 4.78M | 54.61% | ↗ |
| 89 | 2015 | Enrique A. Conterno Senior Vice President and President Diabetes Business Unit | 705.7K | — | 2.27M | — | 852.1K | 42.3K | 3.87M | 58.66% | ↗ |
| 90 | 2015 | Enrique A. Conterno Senior Vice President and President, Lilly Diabetes | 705.7K | — | 2.27M | — | 852.1K | 42.3K | 3.87M | 58.66% | ↗ |
| 91 | 2015 | Enrique A. Conterno Senior Vice President and President, Lilly Diabetes and President, Lilly USA | 705.7K | — | 2.27M | — | 852.1K | 42.3K | 3.87M | 58.66% | ↗ |
| 92 | 2014 | John C. Lechleiter, Ph.D. Chairman, President, and Chief Executive Officer | 1.50M | — | 6.75M | — | 1.79M | 90.0K | 14.48M | 46.61% | ↗ |
| 93 | 2014 | John C. Lechleiter, Ph.D. Chairman, President, and Chief Executive Officer | 1.50M | — | 6.75M | — | 1.79M | 4.45M | 14.48M | 46.61% | ↗ |
| 94 | 2014 | Derica W. Rice Executive Vice President, Global Services, and Chief Financial Officer | 1.02M | — | 2.85M | — | 780.1K | 2.08M | 6.73M | 42.32% | ↗ |
| 95 | 2014 | Derica W. Rice Executive Vice President, Global Services and Chief Financial Officer | 1.02M | — | 2.85M | — | 780.1K | 2.08M | 6.73M | 42.32% | ↗ |
| 96 | 2014 | Derica W. Rice Executive Vice President, Global Services and Chief Financial Officer | 1.02M | — | 2.85M | — | 780.1K | 61.2K | 6.73M | 42.32% | ↗ |
| 97 | 2014 | Jan M. Lundberg, Ph.D. Executive Vice President, Science and Technology, and President, Lilly Research Laboratories | 1.01M | — | 2.25M | — | 771.0K | 578.2K | 4.61M | 48.84% | ↗ |
| 98 | 2014 | Jan M. Lundberg, Ph.D. Executive Vice President, Science and Technology and President, Lilly Research Laboratories | 1.01M | — | 2.25M | — | 771.0K | 60.5K | 4.61M | 48.84% | ↗ |
| 99 | 2014 | Jan M. Lundberg, Ph.D. Executive Vice President, Science and Technology and President, Lilly Research Laboratories | 1.01M | — | 2.25M | — | 771.0K | 578.2K | 4.61M | 48.84% | ↗ |
| 100 | 2014 | Michael J. Harrington Senior Vice President and General Counsel | 765.0K | — | 1.43M | — | 487.7K | 1.38M | 4.05M | 35.15% | ↗ |
| 101 | 2014 | Michael J. Harrington Senior Vice President and General Counsel | 765.0K | — | 1.43M | — | 487.7K | 45.9K | 4.05M | 35.15% | ↗ |
| 102 | 2014 | Enrique A. Conterno Senior Vice President and President Diabetes Business Unit | 682.9K | — | 1.50M | — | 435.3K | 1.28M | 3.90M | 38.51% | ↗ |
| 103 | 2014 | Enrique A. Conterno Senior Vice President and President, Lilly Diabetes | 682.9K | — | 1.50M | — | 435.3K | 41.0K | 3.90M | 38.51% | ↗ |
| 104 | 2014 | Enrique A. Conterno Senior Vice President and President, Lilly Diabetes | 682.9K | — | 1.50M | — | 435.3K | 1.28M | 3.90M | 38.51% | ↗ |
| 105 | 2013 | John C. Lechleiter, Ph.D. Chairman, President, and Chief Executive Officer | 1.50M | — | 6.75M | — | 2.88M | 90.0K | 11.22M | 60.18% | ↗ |
| 106 | 2013 | John C. Lechleiter, Ph.D. Chairman, President, and Chief Executive Officer | 1.50M | — | 6.75M | — | 2.88M | 90.0K | 11.22M | 60.18% | ↗ |
| 107 | 2013 | Derica W. Rice Executive Vice President, Global Services and Chief Financial Officer | 1.01M | — | 2.85M | — | 1.25M | 60.9K | 5.18M | 55.05% | ↗ |
| 108 | 2013 | Derica W. Rice Executive Vice President, Global Services and Chief Financial Officer | 1.01M | — | 2.85M | — | 1.25M | 60.9K | 5.18M | 55.05% | ↗ |
| 109 | 2013 | Jan M. Lundberg, Ph.D. Executive Vice President, Science and Technology and President, Lilly Research Laboratories | 1.00M | — | 2.25M | — | 1.24M | 284.9K | 4.77M | 47.13% | ↗ |
| 110 | 2013 | Jan M. Lundberg, Ph.D. Executive Vice President, Science and Technology and President, Lilly Research Laboratories | 1.00M | — | 2.25M | — | 1.24M | 60.2K | 4.77M | 47.13% | ↗ |
| 111 | 2013 | Michael J. Harrington Senior Vice President and General Counsel | 765.0K | — | 1.31M | — | 786.0K | 310.7K | 3.17M | 41.35% | ↗ |
| 112 | 2013 | Michael J. Harrington Senior Vice President and General Counsel | 765.0K | — | 1.31M | — | 786.0K | 45.9K | 3.17M | 41.35% | ↗ |
| 113 | 2013 | Enrique A. Conterno Senior Vice President and President, Lilly Diabetes | 680.7K | — | 1.50M | — | 699.4K | 40.8K | 3.01M | 49.85% | ↗ |
| 114 | 2013 | Enrique A. Conterno Senior Vice President and President Diabetes Business Unit | 680.7K | — | 1.50M | — | 699.4K | 129.0K | 3.01M | 49.85% | ↗ |
| 115 | 2012 | John C. Lechleiter, Ph.D. Chairman, President, and Chief Executive Officer | 1.50M | — | 5.63M | — | 2.98M | 90.0K | 14.62M | 38.47% | ↗ |
| 116 | 2012 | Derica W. Rice Executive Vice President, Global Services and Chief Financial Officer | 990.0K | — | 2.85M | — | 1.27M | 59.4K | 6.94M | 41.09% | ↗ |
| 117 | 2012 | Jan M. Lundberg, Ph.D. Executive Vice President, Science and Technology and President, Lilly Research Laboratories | 978.5K | — | 2.25M | — | 1.25M | 58.7K | 4.85M | 46.44% | ↗ |
| 118 | 2012 | Robert A. Armitage Senior Vice President and General Counsel | 840.9K | — | 1.50M | — | 955.3K | 50.5K | 3.98M | 37.73% | ↗ |
| 119 | 2012 | Enrique A. Conterno Senior Vice President and President, Lilly Diabetes | 669.5K | — | 1.50M | — | 713.0K | 40.2K | 3.91M | 38.32% | ↗ |
| 120 | 2012 | Michael J. Harrington Senior Vice President and General Counsel | — | — | — | — | — | — | — | — | ↗ |
| 121 | 2011 | John C. Lechleiter, Ph.D. Chairman, President, and Chief Executive Officer | 1.50M | — | 5.63M | — | 2.63M | 90.0K | 16.37M | 34.36% | ↗ |
| 122 | 2011 | John C. Lechleiter, Ph.D. Chairman, President, and Chief Executive Officer | 1.50M | — | 5.63M | — | 2.63M | 90.0K | 16.37M | 34.36% | ↗ |
| 123 | 2011 | Bryce D. Carmine Retired Executive Vice President and President, Lilly Bio-Medicines | 951.7K | — | 2.25M | — | 1.07M | 57.1K | 6.57M | 34.23% | ↗ |
| 124 | 2011 | Derica W. Rice Executive Vice President, Global Services and Chief Financial Officer | 984.2K | — | 2.85M | — | 1.11M | 59.1K | 5.94M | 47.97% | ↗ |
| 125 | 2011 | Jan M. Lundberg, Ph.D. Executive Vice President, Science and Technology and President, Lilly Research Laboratories | 973.8K | — | 2.06M | — | 1.10M | 58.4K | 4.42M | 46.64% | ↗ |
| 126 | 2011 | Robert A. Armitage Senior Vice President and General Counsel | 840.9K | — | 1.50M | — | 840.9K | 50.5K | 3.83M | 39.19% | ↗ |
| 127 | 2011 | Enrique A. Conterno Senior Vice President and President, Lilly Diabetes | 666.3K | — | 1.50M | — | 624.6K | 40.0K | 3.72M | 40.34% | ↗ |
| 128 | 2011 | Michael J. Harrington Senior Vice President and General Counsel | — | — | — | — | — | — | — | — | ↗ |
| 129 | 2010 | John C. Lechleiter, Ph.D. Chairman, President, and Chief Executive Officer | 1.50M | — | 8.18M | — | 2.98M | 90.0K | 16.50M | 49.53% | ↗ |
| 130 | 2010 | John C. Lechleiter, Ph.D. Chairman, President, and Chief Executive Officer | 1.50M | — | 8.18M | — | 2.98M | 90.0K | 16.50M | 49.53% | ↗ |
| 131 | 2010 | Jan M. Lundberg, Ph.D. Executive Vice President, Science and Technology and President, Lilly Research Laboratories | 946.4K | 1.00M | 6.23M | — | 1.21M | 87.8K | 9.55M | 65.17% | ↗ |
| 132 | 2010 | Jan M. Lundberg, Ph.D. Executive Vice President, Science and Technology and President, Lilly Research Laboratories | 946.4K | 1.00M | 6.23M | — | 1.21M | 87.8K | 8.55M | 72.79% | ↗ |
| 133 | 2010 | Bryce D. Carmine Retired Executive Vice President and President, Lilly Bio-Medicines | 947.1K | — | 3.27M | — | 1.21M | 56.8K | 7.74M | 42.27% | ↗ |
| 134 | 2010 | Bryce D. Carmine Executive Vice President and President, Lilly Bio-Medicines | 947.1K | — | 3.27M | — | 1.21M | 56.8K | 7.74M | 42.27% | ↗ |
| 135 | 2010 | Derica W. Rice Executive Vice President, Global Services and Chief Financial Officer | 955.0K | — | 3.27M | — | 1.22M | 57.3K | 6.50M | 50.31% | ↗ |
| 136 | 2010 | Robert A. Armitage Senior Vice President and General Counsel | 836.8K | — | 2.18M | — | 950.6K | 50.2K | 4.54M | 48.03% | ↗ |
| 137 | 2010 | Enrique A. Conterno Senior Vice President and President, Lilly Diabetes | 650.0K | — | 1.96M | — | 692.3K | 39.0K | 3.62M | 54.21% | ↗ |
| 138 | 2009 | John C. Lechleiter, Ph.D. Chairman, President, and Chief Executive Officer | 1.48M | — | 11.25M | — | 3.55M | 90.1K | 20.93M | 53.76% | ↗ |
| 139 | 2009 | Bryce D. Carmine Executive Vice President and President, Lilly Bio-Medicines | 916.7K | — | 4.50M | — | 1.41M | 57.0K | 8.66M | 51.96% | ↗ |
| 140 | 2009 | Bryce D. Carmine Retired Executive Vice President and President, Lilly Bio-Medicines | 916.7K | — | 4.50M | — | 1.41M | 57.0K | 8.66M | 51.96% | ↗ |
| 141 | 2009 | Derica W. Rice Executive Vice President, Global Services and Chief Financial Officer | 892.5K | — | 4.50M | — | 1.22M | 54.8K | 7.65M | 58.85% | ↗ |
| 142 | 2009 | Robert A. Armitage Senior Vice President and General Counsel | 811.2K | — | 3.00M | — | 1.11M | 49.9K | 5.75M | 52.21% | ↗ |
| 143 | 2009 | Steven M. Paul, M.D. Executive Vice President, Science and Technology and President, Lilly Research Laboratories | — | — | — | — | — | — | — | — | ↗ |
| 144 | 2008 | John C. Lechleiter, Ph.D. Chairman, President, and Chief Executive Officer | 1.34M | — | 8.13M | — | 2.71M | 87.1K | 14.48M | 56.10% | ↗ |
| 145 | 2008 | Bryce D. Carmine Executive Vice President and President, Lilly Bio-Medicines | 783.1K | — | 3.75M | — | 1.01M | 53.5K | 6.75M | 55.54% | ↗ |
| 146 | 2008 | Derica W. Rice Executive Vice President, Global Services and Chief Financial Officer | 834.1K | — | 3.00M | — | 1.03M | 86.0K | 5.40M | 55.52% | ↗ |
| 147 | 2008 | Robert A. Armitage Senior Vice President and General Counsel | 778.8K | — | 2.14M | — | 959.4K | 53.1K | 4.47M | 47.87% | ↗ |
| 148 | 2008 | John C. Lechleiter, Ph.D. Chairman, President, and Chief Executive Officer | 1.34M | — | — | — | — | — | 1.34M | 0.00% | ↗ |
| 149 | 2008 | Sidney Taurel Chairman Emeritus | 1.08M | — | — | — | — | — | 1.08M | 0.00% | ↗ |
| 150 | 2008 | Steven M. Paul, M.D. Executive Vice President, Science and Technology | 1.00M | — | — | — | — | — | 1.00M | 0.00% | ↗ |
| 151 | 2008 | Derica W. Rice Senior Vice President and Chief Financial Officer | 834.1K | — | — | — | — | — | 834.1K | 0.00% | ↗ |
| 152 | 2008 | Bryce D. Carmine Executive Vice President and President, Lilly Bio-Medicines | 783.1K | — | — | — | — | — | 783.1K | 0.00% | ↗ |
| 153 | 2008 | Steven M. Paul, M.D. Executive Vice President, Science and Technology and President, Lilly Research Laboratories | — | — | — | — | — | — | — | — | ↗ |
| 154 | 2007 | Sidney Taurel Chairman of the Board and Chief Executive Officer | 1.72M | — | 6.44M | — | 4.04M | 215.0K | 13.01M | 49.52% | ↗ |
| 155 | 2007 | John C. Lechleiter, Ph.D. President and Chief Operating Officer | 1.15M | — | 4.64M | — | 2.16M | 70.8K | 9.33M | 49.73% | ↗ |
| 156 | 2007 | Steven M. Paul, M.D. Executive Vice President, Science and Technology | 960.3K | — | 2.85M | — | 1.53M | 13.5K | 5.96M | 47.88% | ↗ |
| 157 | 2007 | Robert A. Armitage Senior Vice President and General Counsel | 741.7K | — | 2.00M | — | 1.05M | 45.6K | 4.78M | 41.76% | ↗ |
| 158 | 2007 | Derica W. Rice Senior Vice President and Chief Financial Officer | 747.6K | — | 2.00M | — | 1.05M | 78.8K | 4.54M | 43.91% | ↗ |
| 159 | 2007 | Sidney Taurel Chairman Emeritus | 1.72M | — | — | — | — | — | 1.72M | 0.00% | ↗ |
| 160 | 2007 | John C. Lechleiter, Ph.D. Chairman, President, and Chief Executive Officer | 1.15M | — | — | — | — | — | 1.15M | 0.00% | ↗ |
| 161 | 2007 | Steven M. Paul, M.D. Executive Vice President, Science and Technology | 960.3K | — | — | — | — | — | 960.3K | 0.00% | ↗ |
| 162 | 2007 | Derica W. Rice Senior Vice President and Chief Financial Officer | 747.6K | — | — | — | — | — | 747.6K | 0.00% | ↗ |
| 163 | 2007 | John C. Lechleiter, Ph.D. Chairman, President, and Chief Executive Officer | — | — | — | — | — | — | — | — | ↗ |
| 164 | 2007 | Steven M. Paul, M.D. Executive Vice President, Science and Technology and President, Lilly Research Laboratories | — | — | — | — | — | — | — | — | ↗ |
| 165 | 2007 | Robert A. Armitage Senior Vice President and General Counsel | — | — | — | — | — | — | — | — | ↗ |
| 166 | 2007 | Derica W. Rice Executive Vice President, Global Services and Chief Financial Officer | — | — | — | — | — | — | — | — | ↗ |
| 167 | 2006 | Sidney Taurel Chairman of the Board and Chief Executive Officer | 1.65M | — | 5.40M | — | 2.76M | 192.4K | 15.23M | 35.46% | ↗ |
| 168 | 2006 | John C. Lechleiter, Ph.D. President and Chief Operating Officer | 1.11M | — | 3.51M | — | 1.49M | 68.8K | 11.31M | 31.05% | ↗ |
| 169 | 2006 | Steven M. Paul, M.D. Executive Vice President, Science and Technology | 916.2K | — | 1.86M | — | 1.04M | 55.8K | 5.73M | 32.55% | ↗ |
| 170 | 2006 | Robert A. Armitage Senior Vice President and General Counsel | 701.7K | — | 1.39M | — | 705.2K | 42.7K | 4.42M | 31.57% | ↗ |
| 171 | 2006 | Derica W. Rice Senior Vice President and Chief Financial Officer | 615.0K | — | 675.0K | — | 580.5K | 37.7K | 2.67M | 25.30% | ↗ |
| 172 | 2006 | John C. Lechleiter, Ph.D. Chairman, President, and Chief Executive Officer | 1.11M | — | — | — | — | — | 1.11M | 0.00% | ↗ |
| 173 | 2006 | Steven M. Paul, M.D. Executive Vice President, Science and Technology | 916.2K | — | — | — | — | — | 916.2K | 0.00% | ↗ |
| 174 | 2006 | Robert A. Armitage Senior Vice President and General Counsel | 701.7K | — | — | — | — | — | 701.7K | 0.00% | ↗ |
| 175 | 2006 | Derica W. Rice Senior Vice President and Chief Financial Officer | 615.0K | — | — | — | — | — | 615.0K | 0.00% | ↗ |
| 176 | 2006 | Sidney Taurel Chairman of the Board and Chief Executive Officer | — | — | — | — | — | — | — | — | ↗ |
| 177 | 2006 | John C. Lechleiter, Ph.D. President and Chief Operating Officer | — | — | — | — | — | — | — | — | ↗ |
| 178 | 2006 | Charles E. Golden Retired Executive Vice President and Chief Financial Officer | — | — | — | — | — | — | — | — | ↗ |
| 179 | 2006 | Derica W. Rice Senior Vice President and Chief Financial Officer Retired | — | — | — | — | — | — | — | — | ↗ |
| 180 | 2006 | Robert A. Armitage Senior Vice President and General Counsel | — | — | — | — | — | — | — | — | ↗ |
| 181 | 2006 | Steven M. Paul, M.D. Executive Vice President, Science and Technology | — | — | — | — | — | — | — | — | ↗ |
| 182 | 2005 | Sidney Taurel Chairman of the Board and Chief Executive Officer | 1.57M | 2.26M | — | — | — | — | 11.94M | 0.00% | ↗ |
| 183 | 2005 | John C. Lechleiter, Ph.D. President and Chief Operating Officer | 966.4K | 1.04M | — | — | — | — | 6.07M | 0.00% | ↗ |
| 184 | 2005 | Steven M. Paul, M.D. Executive Vice President, Science and Technology | 834.2K | 848.3K | — | — | — | — | 4.40M | 0.00% | ↗ |
| 185 | 2005 | Charles E. Golden Executive Vice President and Chief Financial Officer | 841.6K | 826.9K | — | — | — | — | 4.17M | 0.00% | ↗ |
| 186 | 2005 | Robert A. Armitage Senior Vice President and General Counsel | 632.9K | 538.9K | — | — | — | — | 2.88M | 0.00% | ↗ |
| 187 | 2004 | Sidney Taurel Chairman of the Board and Chief Executive Officer | 1.50M | 1.49M | — | — | — | — | 15.51M | 0.00% | ↗ |
| 188 | 2004 | John C. Lechleiter, Ph.D. President and Chief Operating Officer | 894.0K | 603.5K | — | — | — | — | 7.73M | 0.00% | ↗ |
| 189 | 2004 | Charles E. Golden Executive Vice President and Chief Financial Officer | 813.2K | 548.9K | — | — | — | — | 5.15M | 0.00% | ↗ |
| 190 | 2004 | Steven M. Paul, M.D. Executive Vice President, Science and Technology | 763.0K | 515.0K | — | — | — | — | 5.07M | 0.00% | ↗ |
| 191 | 2004 | Chairman of the Board, President, and Chief Executive Officer | 1.50M | 1.49M | 1.59M | — | — | 72.1K | 4.65M | 34.20% | ↗ |
| 192 | 2004 | Robert A. Armitage Senior Vice President and General Counsel | 578.2K | 338.2K | — | — | — | — | 3.42M | 0.00% | ↗ |
| 193 | 2004 | Executive Vice President, Pharmaceutical Operations | 894.0K | 603.5K | 795.1K | — | — | 42.9K | 2.34M | 34.04% | ↗ |
| 194 | 2004 | Executive Vice President and Chief Financial Officer | 813.2K | 548.9K | 511.1K | — | — | 39.0K | 1.91M | 26.73% | ↗ |
| 195 | 2004 | Robert A. Armitage Senior Vice President, General Counsel | 578.2K | 338.2K | 318.0K | — | — | 27.8K | 1.26M | 25.20% | ↗ |
| 196 | 2003 | Sidney Taurel Chairman of the Board and Chief Executive Officer | 1.43M | 1.19M | — | — | — | — | 9.99M | 0.00% | ↗ |
| 197 | 2003 | Charles E. Golden Executive Vice President and Chief Financial Officer | 789.5K | 444.1K | — | — | — | — | 3.73M | 0.00% | ↗ |
| 198 | 2003 | John C. Lechleiter, Ph.D. President and Chief Operating Officer | 725.6K | 417.7K | — | — | — | — | 3.64M | 0.00% | ↗ |
| 199 | 2003 | Sidney Taurel Chairman of the Board, President, and Chief Executive Officer | 1.43M | 1.19M | — | — | — | 68.8K | 2.70M | 0.00% | ↗ |
| 200 | 2003 | Chairman of the Board, President, and Chief Executive Officer | 1.43M | 1.19M | — | — | — | 68.8K | 2.70M | 0.00% | ↗ |
| 201 | 2003 | Robert A. Armitage Senior Vice President and General Counsel | 550.0K | 268.1K | — | — | — | — | 2.51M | 0.00% | ↗ |
| 202 | 2003 | Steven M. Paul, M.D. Executive Vice President, Science and Technology | 630.1K | 303.9K | — | — | — | — | 1.99M | 0.00% | ↗ |
| 203 | 2003 | Gerhard N. Mayr Executive Vice President, Pharmaceutical Operations | 858.5K | 490.1K | — | — | — | 41.2K | 1.39M | 0.00% | ↗ |
| 204 | 2003 | John C. Lechleiter, Ph.D. Executive Vice President, Pharmaceutical Products | 725.6K | 417.7K | — | — | — | 34.8K | 1.18M | 0.00% | ↗ |
| 205 | 2003 | Executive Vice President, Pharmaceutical Operations | 725.6K | 417.7K | — | — | — | 34.8K | 1.18M | 0.00% | ↗ |
| 206 | 2003 | Pedro P. Granadillo Senior Vice President | 661.4K | 375.6K | — | — | — | 31.7K | 1.07M | 0.00% | ↗ |
| 207 | 2003 | Robert A. Armitage Senior Vice President, General Counsel | 550.0K | 268.1K | — | — | — | 26.4K | 844.6K | 0.00% | ↗ |
| 208 | 2002 | Gerhard N. Mayr Executive Vice President, Pharmaceutical Operations | 820.1K | — | — | — | — | 24.6K | 844.7K | 0.00% | ↗ |
| 209 | 2002 | Executive Vice President and Chief Financial Officer | 789.5K | — | — | — | — | 24.2K | 813.7K | 0.00% | ↗ |
| 210 | 2002 | Charles E. Golden Executive Vice President and Chief Financial Officer | 789.5K | — | — | — | — | 23.7K | 813.2K | 0.00% | ↗ |
| 211 | 2002 | John C. Lechleiter, Ph.D. Executive Vice President, Pharmaceutical Products | 675.0K | — | — | — | — | 20.3K | 695.3K | 0.00% | ↗ |
| 212 | 2002 | Executive Vice President, Pharmaceutical Operations | 675.0K | — | — | — | — | 20.3K | 695.3K | 0.00% | ↗ |
| 213 | 2002 | Pedro P. Granadillo Senior Vice President | 642.1K | — | — | — | — | 19.3K | 661.4K | 0.00% | ↗ |
| 214 | 2002 | Steven M. Paul, M.D. Executive Vice President, Science and Technology | 553.3K | — | — | — | — | 17.1K | 570.4K | 0.00% | ↗ |
| 215 | 2002 | Robert A. Armitage Senior Vice President, General Counsel | 390.4K | — | — | — | — | 73.6K | 464.0K | 0.00% | ↗ |
| 216 | 2002 | Chairman of the Board, President, and Chief Executive Officer | 1.00 | — | — | — | — | 142.9K | 142.9K | 0.00% | ↗ |
| 217 | 2002 | Sidney Taurel Chairman of the Board, President, and Chief Executive Officer | 1.00 | — | — | — | — | 142.4K | 142.4K | 0.00% | ↗ |
| 218 | 2002 | Sidney Taurel Chairman of the Board, President, and | — | — | — | — | — | — | — | — | ↗ |
| 219 | 2002 | August M. Watanabe, M.D. Executive Vice President, Science and Technology | — | — | — | — | — | — | — | — | ↗ |
| 220 | 2001 | Sidney Taurel Chairman of the Board, President, and Chief Executive Officer | 1.39M | 474.4K | — | — | 2.15M | 41.7K | 4.06M | 0.00% | ↗ |
| 221 | 2001 | Gerhard N. Mayr Executive Vice President, Pharmaceutical Operations | 820.1K | 190.7K | — | — | 690.8K | 138.9K | 1.84M | 0.00% | ↗ |
| 222 | 2001 | Charles E. Golden Executive Vice President and Chief Financial Officer | 789.5K | 183.6K | — | — | 690.8K | 23.7K | 1.69M | 0.00% | ↗ |
| 223 | 2001 | Pedro P. Granadillo Senior Vice President | 642.1K | 139.3K | — | — | 560.3K | 19.3K | 1.36M | 0.00% | ↗ |
| 224 | 2001 | John C. Lechleiter, Ph.D. Executive Vice President, Pharmaceutical Products | 675.0K | 146.5K | — | — | 429.8K | 72.8K | 1.32M | 0.00% | ↗ |
| 225 | 2001 | Sidney Taurel Chairman of the Board, President, and | — | — | — | — | — | — | — | — | ↗ |
| 226 | 2001 | August M. Watanabe, M.D. Executive Vice President, Science and Technology | — | — | — | — | — | — | — | — | ↗ |
| 227 | 2000 | August M. Watanabe, M.D. Executive Vice President, Science and Technology | — | — | — | — | — | — | — | — | ↗ |
| 228 | 2000 | Pedro P. Granadillo Senior Vice President, Human Resources and | — | — | — | — | — | — | — | — | ↗ |
| 229 | 2000 | Gerhard N. Mayr Executive Vice President, Pharmaceutical Operations | — | — | — | — | — | — | — | — | ↗ |
| 230 | 2000 | Sidney Taurel Chairman of the Board, President, and | — | — | — | — | — | — | — | — | ↗ |
| 231 | 2000 | Charles E. Golden Executive Vice President and Chief Financial Officer | — | — | — | — | — | — | — | — | ↗ |
| 232 | 2000 | John C. Lechleiter, Ph.D. Executive Vice President, Pharmaceutical Products | — | — | — | — | — | — | — | — | ↗ |
| 233 | 1999 | Sidney Taurel Chairman of the Board, President, and | — | — | — | — | — | — | — | — | ↗ |
| 234 | 1999 | August M. Watanabe, M.D. Executive Vice President, Science and Technology | — | — | — | — | — | — | — | — | ↗ |
| 235 | 1999 | Gerhard N. Mayr Executive Vice President, Pharmaceutical Operations | — | — | — | — | — | — | — | — | ↗ |
| 236 | 1999 | Charles E. Golden Executive Vice President and Chief Financial Officer | — | — | — | — | — | — | — | — | ↗ |
| 237 | 1999 | John C. Lechleiter, Ph.D. Executive Vice President, Pharmaceutical Products | — | — | — | — | — | — | — | — | ↗ |
| 238 | 1999 | Pedro P. Granadillo Senior Vice President, Human Resources and Manufacturing | — | — | — | — | — | — | — | — | ↗ |
| 239 | 1999 | Sidney Taurel Chairman of the Board, President, and Chief Executive Officer | — | — | — | — | — | — | — | — | ↗ |
| 240 | 1999 | Pedro P. Granadillo Senior Vice President, Human Resources and | — | — | — | — | — | — | — | — | ↗ |
| 241 | 1999 | Rebecca O. Goss Senior Vice President and General Counsel | — | — | — | — | — | — | — | — | ↗ |
| 242 | 1998 | Pedro P. Granadillo Senior Vice President, Human Resources and Manufacturing | — | — | — | — | — | — | — | — | ↗ |
| 243 | 1998 | Charles E. Golden Executive Vice President and Chief Financial Officer | — | — | — | — | — | — | — | — | ↗ |
| 244 | 1998 | August M. Watanabe, M.D. Executive Vice President, Science and Technology | — | — | — | — | — | — | — | — | ↗ |
| 245 | 1998 | Pedro P. Granadillo Senior Vice President, Human Resources and | — | — | — | — | — | — | — | — | ↗ |
| 246 | 1998 | Gerhard N. Mayr Executive Vice President, Pharmaceutical Operations | — | — | — | — | — | — | — | — | ↗ |
| 247 | 1998 | Sidney Taurel Chairman of the Board, President, and Chief Executive Officer | — | — | — | — | — | — | — | — | ↗ |
| 248 | 1998 | Rebecca O. Goss Senior Vice President and General Counsel | — | — | — | — | — | — | — | — | ↗ |
| 249 | 1997 | Rebecca O. Goss Senior Vice President and General Counsel | — | — | — | — | — | — | — | — | ↗ |
| 250 | 1997 | Charles E. Golden Executive Vice President and Chief Financial Officer | — | — | — | — | — | — | — | — | ↗ |
| 251 | 1997 | Sidney Taurel Chairman of the Board, President, and Chief Executive Officer | — | — | — | — | — | — | — | — | ↗ |
| 252 | 1997 | Pedro P. Granadillo Senior Vice President, Human Resources and Manufacturing | — | — | — | — | — | — | — | — | ↗ |
| 253 | 1997 | August M. Watanabe, M.D. Executive Vice President, Science and Technology | — | — | — | — | — | — | — | — | ↗ |
CEO compensation breakdown
Proxy statements
Proxy statements (DEF 14A)
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| David A. Ricks | Chairman & CEO | 9M | male |
| Daniel Skovronsky | Chief Scientific & Product Officer and President of Lilly Research Laboratories | 5M | — |
| Anat Hakim | Executive Vice President, General Counsel & Secretary | 3M | female |
| Lucas E. Montarce | Executive Vice President & Chief Financial Officer | 3M | male |
| Jacob S. Van Naarden | Executive VP, President of Lilly Oncology & Head of Corporate Business Development | 3M | male |
| Patrik Jonsson | Executive VP & President of Lilly International | 2M | male |
| Gordon Brooks | Group Vice President, Controller & Corporate Strategy | 1M | male |
| Diogo Rau | Executive VP and Chief Information & Digital Officer | 1M | male |
| Ruth Gimeno | Group Vice President, Diabetes, Obesity & Cardiometabolic Research and Early Clinical Development | — | — |
| Donald A. Zakrowski | Senior Vice President of Finance & Chief Accounting Officer | — | male |
| Eric Dozier | Executive Vice President & Chief People Officer | — | male |
| Frank Cunningham | Senior Vice President of Global Value & Access | — | male |
ESG Rating
ESG Score History DRUG MANUFACTURERS - GENERAL
Benchmark vs Sector
Political Trading Activity (25M)
Senate Trading Activity
| Transaction Date | Disclosed | Senator | State | Owner | Type | Amount | Link |
|---|---|---|---|---|---|---|---|
| 2026-02-13 | 2026-03-24 | Angus King | ME | Spouse | Sale | $1,001 - $15,000 | ↗ |
| 2025-12-29 | 2026-01-16 | Markwayne Mullin | OK | Joint | Purchase | $15,001 - $50,000 | ↗ |
| 2025-12-29 | 2026-01-26 | Angus King | ME | Spouse | Purchase | $1,001 - $15,000 | ↗ |
| 2025-11-21 | 2025-12-08 | John Boozman | AR | Joint | Sale (Partial) | $1,001 - $15,000 | ↗ |
| 2025-11-21 | 2025-12-08 | John Boozman | AR | Joint | Sale | $1,001 - $15,000 | ↗ |
| 2025-10-24 | 2025-11-04 | Shelley Moore Capito | WV | Spouse | Purchase | $1,001 - $15,000 | ↗ |
| 2025-08-22 | 2025-09-13 | John Boozman | AR | Joint | Purchase | $1,001 - $15,000 | ↗ |
| 2025-08-11 | 2025-09-13 | John Boozman | AR | Joint | Purchase | $1,001 - $15,000 | ↗ |
| 2025-04-15 | 2025-05-15 | Tommy Tuberville | AL | Joint | Sale (Full) | $15,001 - $50,000 | ↗ |
| 2025-04-15 | 2025-05-15 | Tommy Tuberville | AL | Joint | Sale | $15,001 - $50,000 | ↗ |
| 2025-03-06 | 2025-03-23 | Ashley Moody | — | Self | Purchase | $100,001 - $250,000 | ↗ |
| 2025-02-10 | 2025-02-21 | Ron Wyden | OR | Spouse | Sale (Full) | $50,001 - $100,000 | ↗ |
| 2025-01-22 | 2025-02-21 | Ron Wyden | OR | Spouse | Purchase | $50,001 - $100,000 | ↗ |
| 2024-12-11 | 2025-08-12 | Markwayne Mullin | OK | Joint | Purchase | $50,001 - $100,000 | ↗ |
| 2024-10-30 | 2024-11-07 | Sheldon Whitehouse | RI | Self | Purchase | $15,001 - $50,000 | ↗ |
| 2024-04-03 | 2024-05-15 | Tommy Tuberville | AL | Joint | Sale (Full) | $15,001 - $50,000 | ↗ |
| 2024-01-03 | 2024-02-14 | Tommy Tuberville | AL | Joint | Sale (Partial) | $15,001 - $50,000 | ↗ |
| 2023-12-14 | 2024-01-18 | Sheldon Whitehouse | RI | Spouse | Purchase | $1,001 - $15,000 | ↗ |
| 2023-10-03 | 2023-11-01 | Markwayne Mullin | OK | Joint | Purchase | $1,001 - $15,000 | ↗ |
| 2023-09-20 | 2023-10-17 | Sheldon Whitehouse | RI | Self | Purchase | $15,001 - $50,000 | ↗ |
House Trading Activity
| Transaction Date | Disclosed | Representative | District | Owner | Type | Amount | Link |
|---|---|---|---|---|---|---|---|
| 2026-04-08 | 2026-05-01 | Lizzie Fletcher | — | — | Sale | $1,001 - $15,000 | ↗ |
| 2026-03-13 | 2026-04-08 | Gilbert Cisneros | CA31 | — | Sale | $1,001 - $15,000 | ↗ |
| 2026-02-26 | 2026-03-09 | David Taylor | OH02 | — | Purchase | $1,001 - $15,000 | ↗ |
| 2026-02-09 | 2026-02-23 | David Taylor | OH02 | — | Sale | $1,001 - $15,000 | ↗ |
| 2026-01-16 | 2026-02-03 | David Taylor | OH02 | — | Sale | $1,001 - $15,000 | ↗ |
| 2025-12-18 | 2026-01-16 | Julie Johnson | TX32 | Joint | Sale | $1,001 - $15,000 | ↗ |
| 2025-12-10 | 2025-12-22 | David Taylor | OH02 | — | Sale | $1,001 - $15,000 | ↗ |
| 2025-11-18 | 2025-12-15 | Gilbert Cisneros | CA31 | — | Purchase | $1,001 - $15,000 | ↗ |
| 2025-11-13 | 2025-12-12 | Julie Johnson | TX32 | Joint | Sale | $1,001 - $15,000 | ↗ |
| 2025-09-23 | 2025-10-10 | Valerie Hoyle | OR04 | Spouse | Sale (Full) | $1,001 - $15,000 | ↗ |
| 2025-08-26 | 2025-09-12 | Ro Khanna | CA17 | — | Sale | $1,001 - $15,000 | ↗ |
| 2025-08-14 | 2025-09-12 | Julie Johnson | TX32 | Joint | Sale | $1,001 - $15,000 | ↗ |
| 2025-08-14 | 2025-09-03 | David Taylor | OH02 | — | Purchase | $15,001 - $50,000 | ↗ |
| 2025-08-14 | 2025-09-03 | David Taylor | OH02 | — | Purchase | $1,001 - $15,000 | ↗ |
| 2025-07-16 | 2025-08-13 | Lisa McClain | MI09 | Spouse | Sale (Full) | $1,001 - $15,000 | ↗ |
| 2025-07-10 | 2025-08-13 | Lisa McClain | MI09 | Spouse | Purchase | $1,001 - $15,000 | ↗ |
| 2025-07-02 | 2025-08-08 | Ro Khanna | CA17 | — | Purchase | $1,001 - $15,000 | ↗ |
| 2025-06-09 | 2025-08-13 | Lisa McClain | MI09 | Spouse | Sale (Partial) | $1,001 - $15,000 | ↗ |
| 2025-06-06 | 2025-07-10 | Ro Khanna | CA17 | — | Purchase | $1,001 - $15,000 | ↗ |
| 2025-06-03 | 2025-07-15 | Jonathan Jackson | IL01 | Joint | Sale | $15,001 - $50,000 | ↗ |
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for LLY
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
